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ABSTRACT
The human placenta of different gestational ages is a readily available source for
isolation of adult mesenchymal stem cell (MSC) for potential use in regenerative
therapies. The chorionic villous region, the largest component of a placenta that
interfaces with the maternal circulation, is a rich source of placental MSCs
(PMSCs). To remain multipotent, PMSCs are best maintained in culture
conditions that mimic the in vivo microenvironment. Insulin like growth factors
(IGFs, IGF-I and -II) and oxygen tension are two of the most important
microenvironmental factors in the placenta. They are of low concentration or
tension respectively, at early gestation, and increase as pregnancy progresses.
In this thesis, we investigated the role and cellular mechanisms by which IGFs
and low oxygen tension determine PMSC fate. The main hypothesis is that the
interaction between IGFs and oxygen tension determines PMSC fate towards
self-renewal or differentiation. We used cell proliferation assay, immunoblotting,
real-time PCR, and cell monolayer staining to evaluate the role of IGF and
oxygen tension on PMSC multipotency and differentiation. We found that low
oxygen tension was a major determinant of PMSCs proliferation and
multipotency, and to delay differentiation. Also, PMSC response to IGF
stimulation and low oxygen tension was gestational age dependent — preterm
PMSCs being more multipotent and proliferative than term PMSCs. IGF-I and
IGF-II promoted PMSC proliferation and multipotency via IGF-IR or IR,
depending on oxygen tension. IGFs enhanced PMSC differentiation towards the
osteogenic lineage which was transduced by ERK1/2 and AKT signaling
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cascades. We conclude that IGFs and oxygen tension act synergistically or
antagonistically, mimicking in vivo microenvironmental conditions, to determine
PMSC fate towards multipotency or differentiation. The appropriate combination
of IGFs and oxygen tension can be used to maintain stem cells in multipotency,
or to be induced towards a specific progenitor cell lineage for successful use in
tissue regeneration therapies.
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CHAPTER ONE
INTRODUCTION

2
1.1. Stem Cell Origin
1.1.1. Stem cell classification and potency
Stem cells are naïve unspecialized clonal cells that have the capacity for selfrenewal and differentiation (1). Cells from an early embryo (e.g. morula) have the
greatest potential to differentiate and can give rise to the whole embryo or
organism, including germ cells and extraembryonic tissues. Most stem cells are
derived from later gestation embryos and are classified according to their
differentiation potential into pluripotent, multipotent, oligopotent and unipotent
cells. Also, stem cells are classified according to their origin and derivation
procedure into embryonic (ESCs), adult mesenchymal (MSCs), tissue-resident
and induced pluripotent stem cells (iPSCs), where the first three are naturally
occurring and are found in vivo, while the latter are generated in vitro from
reprogramming terminally differentiated cells. ESCs are pluripotent, isolated from
the inner cell mass of the blastocyst and can differentiate into any cell type of the
three germ layers; adult MSCs are multipotent stem cells and have a limited
proliferation capacity and a more restricted differentiation lineage (2). Recently,
the development of iPSCs, as autologous ES-like cells that can be an alternative
to allogeneic ESCs for tissue regeneration therapies, has generated much
excitement. They are developed by somatic cell nuclear transfer (somatic
nucleus transfer into anuclear oocyte) or reprogramming (using a combination of
4 transcription factor OCT4, SOX2, KLF4, c-MYC, NANOG, and microRNA
binding protein LIN28) (2-4).
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The three transcription factors OCT4, SOX2 and NANOG are major regulatory
triad of human ES cell fate and major transcription factors that are induced to
develop iPSCs (3-6). Each of these transcription factors has a major role in
repressing the differentiation process towards a specific lineage: OCT4
represses extraembryonic and epiblast-derived lineages, SOX2 represses
mesendoderm differentiation and NANOG represses embryonic ectoderm
differentiation (5). Among the three transcription factors, OCT4 is the only
indispensible transcription factor to generate iPSCs, and its transfection into
neural progenitor cells as a single factor is sufficient to generate iPSCs (3, 4, 79). OCT4, a POU homeodomain transcription factor, is regarded as the master
regulator and gatekeeper of pluripotency to keep stem cells in an undifferentiated
state (8, 10-12). For this critical role in maintaining pluripotency, OCT4
expression is tightly regulated, whereas under- or over-expression leads to
differentiation (10). Also, OCT4 is not lost in committed lineage progenitor cells of
the three germ layers beyond gastrulation suggesting that it plays an important
role in the commitment of pluripotent stem cells into somatic lineages (8). Indeed,
pluripotent ESCs/iPSCs with low OCT4 levels fail to exit the pluripotent state
upon the induction of differentiation, and were rescued to differentiate into three
germ layers by the restoration of OCT4 expression (13).
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1.1.2. Adult mesenchymal stem cells
Mesenchymal stem cells (MSCs) or adult mesenchymal stem cells are
multipotent cells that have the capacity for self-renewal and differentiation into
different cell types of one or more lineages of three germ layers. The first
discovery of the existence of multipotent stem cell population was by Till and
McCulloch in 1961 (14), which was followed by the first bone marrow MSCs
isolated in 1968 by Friedenstein (15). To date, MSCs have been isolated from
every mature organ and tissue including skeletal muscle (16), adipose tissue
(17), deciduous teeth (18), umbilical cord blood (19), peripheral blood (20), brain
(21), etc. Several biological markers characterize stem cells of different origins,
and are positive for CD73, CD105, CD117, CD29, CD44, CD71, CD90, CD106,
CD120a, and CD124, and negative for hematopoietic markers CD34, CD45 and
CD14 (22-24). It has been demonstrated that MSCs have the potential to
differentiate into several major mesodermal cells including osteogenic,
chondrogenic, adipogenic (25) and endothelial (26) cells, and ectodermal cells,
including neuronal cells (27) in a microenvironment-dependent manner.

1.2. Human Placenta – A Source of Stem Cells
1.2.1. Placental development and the fetal compartment
The human chorioallantoic placenta is the main organ that supports fetal growth
and survival by offering nutrient supply and eliminating waste products (28). The
optimal growth and development of the placenta is essential, and any
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abnormality in development is responsible for many pregnancy complications
including miscarriages, preterm birth, preeclampsia and fetal growth restriction
(FGR) (28, 29). In a normal pregnancy, the human placenta is developed as
single organ in which maternal and fetal compartments are brought together, and
is delivered after the delivery of the baby at term gestation.

The

chorionic

villi

are

the

functional

units

of

the

placenta

where

oxygen/nutrient/waste exchange occurs between the uteroplacental and
fetoplacental circulations without intermixing of blood. Each chorionic villus is
composed

of

three

layers:

villous

trophoblast

(syncytiotrophoblasts/

cytotrophoblasts), villous stroma (mesenchymal cells/Hofbauer cells/fibroblasts),
and fetal vascular endothelium (vascular smooth muscle cells/ perivascular
cells/endothelial cells) (30). Trophoblasts are the first cells to be in direct contact
with the maternal uterine environment, and therefore play a critical role in
preventing an immune rejection of the conceptus and facilitating implantation. To
form placental blood supply, trophoblasts invade the decidua and remodel spiral
arteries in the uterus (28-30). By 10-12 weeks of gestation, maternal blood flows
from the spiral arteries to fill up the intervillous space surrounding the villi for
oxygen/nutrient/waste exchange. The stromal layer of the chorionic villous is a
rich source of mesenchymal stem cells (MSCs), available for vasculogenesis and
angiogenesis, and is located between the syncytiotrophoblasts/cytotrophoblasts
layer that is in direct contact with maternal blood and the fetal endothelium that is
in direct contact with fetal circulation (30). Also within the stromal layer, Hofbauer
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cells, the antigen-presenting macrophages, are abundantly present to maintain
host defense as they lie closely to cytotrophoblast cells and fetal endothelial cells
(31). Fetal derived endothelial cells, surrounded by pericytes, form the capillary
network of the chorionic villi. These pericytes play a significant role in blood
vessel regeneration and are therefore important to maintain micro-vessel integrity
and stability (30). Overall, the placenta’s vital role in supporting fetal development
is to offer the embryo and fetus an optimal environment for growth and
development.

1.2.2. Stem cell populations in the placenta
Placenta is a readily available, non-invasive and ethically less controversial
source of adult mesenchymal stem cells (MSCs). These stem cells have been
isolated successfully from the umbilical cord blood, umbilical cord, amniotic fluid,
fetal membranes and placental tissue (chorion) (32). Placental MSCs were also
isolated from the tissues of maternal origin, the decidua basalis and the decidua
parietalis (32). Although, MSCs can be isolated from fetal or maternal tissues,
placental MSCs are fetal in origin, and have the ability to expand at a higher
proliferation rate and passage number in vitro than bone marrow MSCs (32), the
more common MSC used in tissue regeneration therapies.
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Reproduced from Pathology of the Human Placenta, 3rd Ed., Benirschke, K., and Kaufmann, P. Page 62. Copyright 1995, with
permission from Springer-Verlag, NY; and from Fetal and neonatal physiology, edited by Richard A. Polin William W. Fox. Pages 47
– 55. Copy right 1992, with permission from Elsevier Limited,

Figure 1.1. Mature Human placenta in situ. The human placenta is a discoidal type multivillous hemomonochorial structure. The
intervillous space is filled with maternal blood delivered by the spiral arteries allowing nutrient and waste exchange between the
fetal and maternal circulations. The chorionic villous is the functional unit of the placenta from a fetal origin that is made up of
several cell types (syncytiotrophoblasts, cytotrophoblasts, Hofbauer cells, stromal fibroblasts, pericytes, endothelial cells, and
mesenchymal stem cells).
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1.2.3. Placental mesenchymal stem cells (PMSCs) from chorionic villi
In this thesis, placental mesenchymal stem cells (PMSCs) were isolated from the
chorionic villi (33) (Fig. 1.1). PMSCs originate from a single cell population from
the extraembryonic mesoderm of the developing totipotent fertilized egg, which
invades the chorionic villous core along with cytotrophoblasts at 21 days post
conception (33-35). These PMSCs play an important role early in placental
vasculogenesis and angiogenesis as they differentiate into four cell types:
macrophage-like mesenchymal cells (Hofbauer cells), haemangioblastic cords
(multipotent precursor of hematopoietic and endothelial cells), pericytes (can be
precursors of vascular endothelial cells) and stromal fibroblasts (34). These
PMSCs are isolated from early and late gestation placentae (Fig. 1.1), using
mechanical and enzymatic digestion with trypsin, collagenase and DNase (36)
followed by Percoll density gradient separation similar to hematopoietic MSC
isolation (37). PMSCs proliferate for at least up to 10 passages without alteration
of phenotype and morphology in vitro, and have differentiation potential for all
mesodermal

lineages

(adipogenic,

chondrogenic,

osteogenic,

skeletal

myogenic), ectodermal lineages (neuronal), and endodermal lineage (beta cells)
(33). These cells are promising candidates for tissue regeneration therapy for
their availability, abundance, ease of processing, and wide range of
differentiation lineages. However, optimal culture conditions are required to
maintain prolonged proliferation and maintenance of pluripotency and complete
homogeneous differentiation in vitro. This can be achieved by understanding the
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in vivo microenvironment of the placenta, and thereby, developing in vitro culture
conditions that mimic in vivo conditions.

1.3. Stem Cell Microenvironment
1.3.1. Physical compartment
Stem cell microenvironment or “niche” is an anatomical structure, including
cellular and acellular components, that integrates local and systemic factors to
regulate stem cell pluri- or multi-potency, proliferation, differentiation, survival and
localization (Fig. 1.2) (38). Proliferation and differentiation of stem cells are
maintained by the surrounding microenvironment via several clues including
physical, structural, neural, humoral, paracrine, autocrine, and metabolic
interactions (39). Therefore, a combination of different microenvironmental
signals would determine the proliferative state of stem cells depending on the
active process of tissue regeneration causing either cell proliferation or
quiescence (40). In addition, the components present in the microenvironment,
such as growth factors, cytokines, extracellular matrix, chemokines and oxygen
levels, are critical for limiting or facilitating the MSC survival and propagation of
stem cells (symmetric division) or differentiation to more specialized committed
cells (asymmetric division).
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Low
Oxygen
Tension

IGFs

IGFs

Figure 1.2. Stem cell niche in vivo. The stem cell niche is a complex
compartment surrounding stem cells directing their identity preservation via
cellular and acellular components. Various clues are exchanged between cells,
extracellular matrix, growth factors, soluble factors and oxygen tension to direct
the stemness state depending on growth and regeneration demand. Among
growth factors, IGFs are derived via either paracrine or endocrine sources.
Oxygen tension supplied by blood circulation is usually low in stem cell niches.
IGFs and low oxygen tension alone or in combination may be major determinants
of stem cell fate.
Reproduced from Nature Reviews Molecular Cell Biology 9, Jones L and Wagers
AJ. No place like home: anatomy and function of the stem cell niche. Pages12
Copyright 2008, with permission from Nature Publishing Group.
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1.3.2. Oxygen tension and growth factor modulation
Low oxygen tension in the stem cell microenvironment is being recognized as an
important signal that regulates stem cell proliferation and differentiation (41). The
notion of considering stem cell culture under room air (20% oxygen) in a cell
culture incubator as “normoxia”, compared with a decreased ambient oxygen as
“hypoxia”, has to be changed as oxygen tension in natural niches is low and
termed “physiologic normoxia” (42). Oxygen tension, in many organs and tissues,
ranges from 2-9% (14-65 mmHg) (43). In particular, oxygen levels reach 1.5-8%
O2 in the mammalian reproductive tract, 1-2% O2 in bone marrow, and ~3% O2 in
adipose tissue (41). Therefore, maintaining stem cells in low oxygen tension in
vitro is more physiological than 20% O2 (room air condition) used in standard cell
culture. Low oxygen tension can increase the rate of MSC proliferation and
potentiate or diminish differentiation (depending on the differentiation lineage);
and also a hypoxic preconditioning of MSC can improve engraftment and survival
for transplantation (44).

Besides its direct effect on maintaining on undifferentiated state, low oxygen
tension can alter growth factor expression and secretion. Recently, MSCs were
described as “medicinal secretory cells” that increase the secretion of trophic
factors

and

immunomodulatory

cytokines

offering

a

regenerative

microenvironment for injured tissues (45). Low oxygen tension is shown to
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increase MSC gene expression and secretion of several factors involved in cell
growth and survival including FGF2, HGF, VEGF-D, PGF, PBEF1, HB-EGF and
MMP9 (46). IGF-I is another growth factor synthesized by MSCs, which induces
an anti-apoptotic and pro-survival signals (47). Therefore, in ischemic or hypoxic
tissues, MSCs are recruited by secreted cytokines and chemokines modulate
survival, growth and angiogenesis, and facilitate recovery and repair of injured
tissues. Hence, MSCs are increasingly recognized as important candidates for
tissue regeneration either by direct differentiation or by supporting the repair
mechanism to correct organ physiology and function — where low oxygen
tension plays a significant role.

1.3.3. Growth factor signaling
In the stem cell niche, a combination of growth factor signaling inputs can control
the stem cell state between proliferation and differentiation. In one study, the
signaling of TGFβ/activin/nodal was required to maintain an undifferentiated state
of hESCs (48). Another study showed that IGF-II and its signaling via the IGF-IR
are important to maintain self-renewal and pluripotency in vitro with a
requirement of bFGF/FGF-2 to maintain a supportive fibroblast cell population
(49). The expression and signaling of many RTKs, such as FGFR1-3, EGFR
(ERBB2 and ERBB3), VEGFR2, KIT, RET, and the IGF-IR, are important for
stem cell multipotency and fate changes (50), where significant signaling
cascades, yet to be elucidated, can maintain stem cell character. For application

13
in tissue regeneration, the use of xeno-free and animal-free cell culture
conditions are desired to eliminate rejection and an immune response. For this,
knock-out serum replacement (KOSR) media is becoming a preference for
culture of ESCs, supplemented with growth factors to maintain pluripotency (51).
Growth factors used in combination with KSOR media, including but are not
limited to, bFGF/FGF2, activin A, HRG1, IGF-II and IGF-I (51).

In addition to a combination of growth factor signaling required for stem cell
pluripotency, the extracellular matrix (ECM) complex (e.g. matrigel) or a single
component, (e.g. fibronectin, laminin, collagen, etc.) is used to support a feederfree culture of hESCs (51). One of the benefits of the ECM is in facilitating stem
cell attachment and spreading, therefore enhancing cell proliferation and
migration (52). Also, the extracellular matrix in stem cell niches can act as
reservoir of growth factors to regulate their bioavailability and generate a gradient
important to direct stem cell proliferation vs. differentiation (53). In the neural
stem cell niche, heparan sulfate proteoglycans are shown to capture and
concentrate FGF-2 from the milieu to support neural stem cell function (54). Also,
in the ECM, integrins function cooperatively with signaling pathways to mediate
receptor

transactivation,

coordination,

modulation

and

receptor

compartmentalization (53). For example, a crosstalk occurs between the IGF-IR
and β1-integrin to modulate cell proliferation, migration and differentiation (52).
Therefore, growth factor signaling can be manipulated by the stem cell niches.
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By deconstructing the stem cell niche, the individual role of signaling pathways –
such as the IGF axis – will need to be delineated.

1. 3.4. Placental microenvironment changes during gestation stages
1.3.4.1 Oxygen tension
Oxygen tension and growth factor availability in the microenvironment of the
developing human placenta continually change throughout gestation. The human
conceptus requires low oxygen tension for healthy implantation into the external
layer of the endometrium (55). Moreover, low oxygen tension is maintained
during the first 10 days post-fertilization until trophoplasts develop and dip their
processes in the maternal-blood. The placental tissue develops further and the
oxygen level fluctuates in both maternal (endometrium) and fetal sides. At 8-10
weeks of gestation, oxygen tension is very low, on the average of 17.9 mm Hg or
2.35% O2 on the fetal side, which is lower than the maternal side at 39.6 mm Hg
or (5.21% O2) (Fig. 1.3). Later, at 12-13 weeks of gestation the oxygen tension
rises to reach 60.7 mm Hg or (7.98% O2) at the fetal side compared with 46.5
mm Hg or (6.12% O2) at the maternal side (Fig. 1.3) (56). This change between
the first and second trimester occurs due to the rise in the oxygen tension (PO2)
at the intervillous space (IVS) which is facilitated by the active arterial blood flow
between the IVS and the spiral arteries with low vascular resistance (55). Thus,
the human embryo exists in a low oxygen environment, at least in the first
trimester (0-12 weeks), when organogenesis occurs, indicating a major role for

15

Figure 1.3. Low oxygen tension and IGF levels in the placental
microenvironment during gestation. Oxygen tension and IGF concentration are
constantly changing during gestation. Low oxygen tension starts at near anoxic
levels during implantation and rises upon the placental growth and connection
with the maternal spiral arteries to reach 60 mmHg at early gestation and is
maintained through gestation thereafter. IGF-I is expressed around 12 weeks of
gestation, while IGF-II is expressed earlier at 6 weeks. Both IGF expression
gradually increases during gestation. At term gestation, IGF-I concentration is
100 ng/mL and IGF-II, 300 ng/mL, as measured in the umbilical cord blood.
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low oxygen tension during development (55). Therefore, studying the behavior of
placental mesenchymal stem cells (PMSCs) isolated at different gestation times
(preterm vs. term) would unravel some aspects of placental development from
the low oxygen tension microenvironment in the first trimester, to a well
vascularized oxygenated tissue at the end of the third trimester (Fig. 1.3).

1.3.4.2. Insulin-like growth factors
Insulin-like growth factors (IGFs - IGF-I and IGF-II) represent one of the most
important growth factor systems in cell growth and development, and cell-fate
changes through several mitogen activation cascades (57-60). IGFs have a
prominent role in pregnancy and fetal development by promoting proliferation,
differentiation and survival of various types of placental cells (61). In human
pregnancies, circulating IGF levels correlate proportionally with placental and
fetal weights, where reduced levels due to nutrition can lead to fetal growth
restriction (62). Both IGF-I and IGF-II are expressed in all cell types in the
placenta as early as six weeks of gestation (63). IGF-II is important in facilitating
the cytotrophoblast invasion of the maternal decidua early in human pregnancy
and contributes to the placental vascularization, whereas, IGF-I is implicated with
the placental development in the second trimester to term gestation (62). The
exact IGF concentration in the immediate microenvironment of the chorionic villi
during different gestational stages is not known, but the levels described are
those measured in the umbilical cord blood. In a fully developed term placentae,
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the IGF-I concentration is 71 – 132 ng/mL with IGF-II concentration being threefold higher at 246 – 356 ng/mL in the umbilical cord blood (Fig. 1.3) (64).
Therefore, the effect of IGFs on PMSCs during different gestational stages may
change depending on IGF ligand abundance and IGF-IR.

1.4. Cellular Signaling and Mechanistic Regulation
1.4.1. Low oxygen tension and hypoxic regulation
Oxygen homeostasis is essential for the healthy physiology of an organism as
well as to a single cell. Oxygen should be available in a narrow range to maintain
the cellular health. The lower limit of this range is identified by the oxygen tension
needed to maintain a reservoir of high-energy ATP molecules via aerobic
respiration, which requires O2 for the electron transport chain (ETC) (65). On the
other hand, the oxygen tension should not exceed a threshold (the top limit) in
order to prevent the generation of reactive oxygen species (ROS) that have a
destructive effect on the structure and function of macromolecules (65). In low
oxygen tension, reduced cellular energy demand is met by glycolysis, which is
adequate for maintaining stem cell pluripotency and generating iPSCs (66, 67).
At low oxygen tensions (hypoxia), oxygen-sensing mechanism stabilizes the
formation of the hypoxia inducible factor (HIF). Mainly, the HIF-1 system can
compensate for the production of ATP, under hypoxic conditions, by increasing
the transcription levels of several genes that control glycolysis, angiogenesis and
erythropoiesis, and therefore, indirectly promotes cell survival (68). Formed
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under hypoxic conditions, HIF-1 is a heterodimer complex of α- and β- subunits,
where both are basic-helix-loop-helix (bHLH) proteins containing PAS (PERARNT-SIM subfamily of bHLH) domains (69). At the protein level, the β-subunit
(HIF-1β/ARNT) is continuously expressed and not degraded, while the α- subunit
(HIF-1α) is regulated in the cytoplasm by regulatory proteins, such as prolyl
hydroxylase domains -1, -2 and -3 proteins (PHDs), where PHD-2 utilizes
molecular oxygen as a co-substrate and hydroxylates HIF-1α under normal
oxygen tension oxygen (68, 70). Under low oxygen tension conditions, PHD-2
cannot deliver hydroxyl groups on proline residues, and therefore, HIF-1α is
stabilized by preventing the interaction with the von Hippel–Lindau protein and
ubiquitin. Hence, HIF-1α is not targeted to the 26S proteasome for degradation
(68, 70-72). At this stage, HIF-1 accumulates in the cytoplasm, translocates into
the nucleus and dimerizes with HIF-1 to form the nuclear dimeric HIF-1 protein
(Fig. 1.4B). HIF-1 can bind to the hypoxia responsive element (HRE) defined by
the core sequence 5’-RCGTG-3’ (R = A or G), in promoters of target genes
responsible for proliferation and survival (68, 71). At least seventy genes are
regulated by HIF-1, encoding cell surface receptors, extracellular matrix proteins
and enzymes, angiogenic growth factors, cytoskeletal proteins, glucose
transporters and glycolytic enzymes, proapototic factors, and other transcription
factors (73). In addition, insulin and IGF-I share with hypoxia, the ability to
activate transcription through the HRE, where HIF-1 is their main target to induce
gene transcription (74). HIF-1α is stabilized by its direct phosphorylation by
ERK1/2 and not by p38 MAPK or c-Jun N-terminal kinase (75). Therefore,
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manipulating PMSC microenvironment with IGFs can change the stem cell fate
by the induction of various hypoxia genes, which can be achieved directly by low
oxygen tension or indirectly by HIF-1α phosphorylation.

1.4.2. Insulin-like growth factor system
1.4.2.1 Ligands and receptors
Insulin-like growth factors (IGFs; IGF-I and -II) are polypeptides that stimulate the
differentiation and self-renewal of many types of cells including stem cells (49),
mainly through the interaction with the IGF-I receptor (IGF-IR). IGF-IR shares a
structural homology domain with the insulin receptor (IR), which is expressed in
two isoforms IR-A and IR-B, and can form hybrids (HR-A and HR-B) with the
IGF-IR. IGF-II can also bind to its specific receptor, IGF-IIR, and with a higher
affinity than IGF-I to the insulin receptor (IR). Both IGF-I and -II can bind to the
hybrid receptor IGF-IR/IR with variable affinities (76). IR, IGF-IR and IR/IGF-IR
hybrids are mitogenic RTKs, whereas IGF-IIR is not. IGF-II binding affinity to IRA is similar to insulin, however, it can activate the mitogenic signaling cascade,
which is a different response than activation of IR (77). IGF-IR is more sensitive
to IGF-I with a Kd of 1 nM, whereas, with a 10-fold lower affinity to IGF-II (78).
Six IGF-binding proteins (IGFBPs, IGFBP-1 to -6) regulate the bioavailability of
the IGF ligand in the extracellular vicinity of the receptors to sequester or release
the IGFs, therefore, modifying the IGF actions (79).
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Upon ligand binding, IGF-IR initiates mitogenic signals by activating the two main
signal transduction pathways and effectors: the phosphoinositide 3-kinase
(PI3K), AKT/PKB and the extracellular signal-regulated kinase (ERK1/2) (Fig.
1.4A) (80). Through these molecules, IGF-IR can induce transcriptional activity
that would promote survival, self-renewal and differentiation (81, 82). The
downstream signal of IGF-IR is dependent on the differential phosphorylation
pattern of its β-subunit and the resultant tyrosine residues available to bind
adaptor molecules or kinase effectors such as, PI3K, AKT, RAS/RAF and
ERK1/2 (83, 84).

1.4.2.2. IGF-IR, adaptor molecules and signaling cascades
IGF-IR is a transmembrane tetramer receptor that exists as heterodimers
composed of two α and β hemireceptors linked by disulfide bonds in a β–α–α–β
structure (Fig. 1.5) (85). IGF-IR has three properties related to cell growth, where
it (i) promotes survival and protects from apoptosis both in vivo and in vitro, (ii)
stimulates cell-growth, and (iii) is required for the establishment and maintenance
of a tumor-like phenotype (83).

Figure 1.4. IGF signaling in low oxygen tension conditions. A) IGF-IR is the major signaling receptor to interact with IGF-I and IGFII to trigger one of the two classical signaling cascades: the RAS/RAF/MEK/ERK or the PI3K/AKT pathways, which facilitate protein
phosphorylation downstream in the cytoplasm and nucleus. B) In low oxygen tension, the hypoxia inducible factor system is
stabilized and formed by the dimerization of the α and β subunits to form a transcription factor that translocates to the nucleus to
induce gene transcription.
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Upon activation of the extracellular α subunits of the IGF-IR, autophosphorylation
of tyrosine residues (Y1131, 1135, 1136) on the β-subunits creates high affinity
binding sites for signaling adaptor molecules and substrates. SHC and the insulin
receptor substrate-1 (IRS-1) are two adaptor/substrate molecules interact with
Tyr-950 at the NPXY motif of the β subunit of IGF-IR (Fig. 1.5) (83, 86). For the
ERK1/2 signaling pathway, SHC interacts directly with the IGF-IRβ (at Tyr-950)
which gets phosphorylated at tyrosine residues (Tyr-317 and/or Tyr-239/240) to
recruit the SH2 domain binding of GRB2. In turn, GRB2 interacts via its SH3
domain with SOS that subsequently activates c-RAS by exchanging GTP for
GDP leading to the sequential phosphorylation of RAF, MEK1/2 and then
ERK1/2 (Fig. 1.4) (86-91). To activate the PI3K/AKT signaling, p85, the
regulatory subunit of PI3K, interacts directly with IGF-IRβ at YAHM motif at Tyr1316 independent of Tyr-950 — the site for IRS-1 and SHC binding (Fig. 1.5)
(92). The C-terminal c-SH2-domain of p85 is responsible for binding with the
carboxy-terminal of IGF-IRβ, while both n/c-SH2 domains of p85 bind to the IR
corresponding C-terminal motif (YTHM at Tyr-1322) causing a more efficient and
stronger interaction between IR and p85 than that with IGF-IR (92, 93).
Therefore, the difference between the binding of p85 to either of IGF-IR and IR
would exert different biological responses due to the dose of IGF-I or -II that can
activate both IGF-IR and IR. However, IR has a 100-fold lower affinity to IGF-I
than that for insulin to exert an effect (58). Besides the direct interaction with the
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Figure 1.5. IGF-IR binding domains. IGF-IR is a class-2 transmembrane receptor
tyrosine kinase with two extracellular α-subunits and two β-subunits that extends
intracellularly spanning the membrane. The α-subunits contain the ligand binding
domain, while the β-subunits contain the kinase function for autophosphorylation
and binding to various adaptors.
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IGF-IRβ, the ERK1/2 and the PI3K/AKT signaling is activated by the indirect
interaction via IRS-1 recruited to IGF-IRβ. IRS-1 is a main adaptor of the IGF-IR
implicated with the mitogenic effect of IGF-IR, inhibition of apoptosis and
transformation of cells into the tumoral cells when over-expressed, whereas, its
downregulation has been associated with the inhibition of differentiation and the
induction of apoptosis (80, 94). It has been shown that the N-terminal domain of
IRS-1 binds to the p-IGF-IRβ to induce over 20 potential phosphorylated sites
available to recruit GRB2, NCK, the p85 regulatory subunit of PI3K, the tyrosine
phosphatase SH-PTP2, SRC-like kinase FYN and the Ca2+-ATPases SERCA1
and AERCA2 (86, 95). The phosphorylation of IRS-1 at Tyr-895 recruits GRB2
and

transduces

the

signal

through

the

ERK1/2

(87),

whereas,

the

phosphorylation of Tyr-612/-632 would activate the PI3K signaling by recruiting
p85 binding (96). Therefore, both ERK1/2 and PI3K/AKT signaling pathways are
also activated by IGF-IR via the indirect binding of GRB2 and p85, respectively,
to the IRS-1 (86, 87, 91), and therefore, a wider range of interacting adaptors can
be mediated to define the signaling cascade. In the stem cell niche, the
microenvironmental components (oxygen tension and IGFs) define the signaling
cascades in stem cells to promote either self-renewal or differentiation depending
on receptor activation and the combination of signaling cascade.
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1.5. Stem Cell Differentiation and Fate Specification
1.5.1. Stem cell differentiation conditions
Two approaches are undertaken to induce stem cell differentiation using either
intrinsic

nuclear

reprogramming,

via

transcription-factor-mediated

reprogramming, or extrinsic, via growth-factor-mediated stimulation (97). Similar
to iPSC generation, intrinsic nuclear reprogramming has been successful but is
still limited to acquire only few lineages, such as cardiomyocytes, hepatocytes,
and neurons due to the limitation of known reprogramming factors (97). For this
purpose, reprogramming and de-differentiation to an iPSC is required. However,
to cover a wider range of differentiation lineages, extrinsic growth factor
stimulation is the solution to acquire cells from all three germ layers. In vivo, the
natural route of stem cell differentiation is mediated via extrinsic growth factor
signaling within the microenvironment. In their niche, ESCs are in quiescent
dormant state that is maintained by three interactions with the niche components:
the supportive cellular contact, the ECM, and the paracrine growth factor
signaling (51). Thus, manipulating any of these conditions will disturb the natural
niche of the stem cell causing asymmetrical division towards a differentiated
phenotype. In vitro, differentiation is triggered by withdrawing maintenance
growth factors or stimulating by differentiation promoting growth factors and
molecules (98, 99). As shown in Fig. 1.6, differentiation of adult MSCs follow
specific differentiation protocols using varying combinations of growth factors and
chemical compounds, such as butylated hydroxyanisole and NGF for neuronal
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differentiation; BMP-12 for tendocyte differentiation; dexamethasone, 3-isobutyl1-methylxanthine, insulin and indomethacin for adipogenic differentiation;
monothioglycerol, HGF, oncostatin, dexamethasone, FGF4, insulin, transferrin
and selenium for hepatocytic differentiation; b-FGF and VEGF for endothelial
differentiation; TGF-β1, insulin, transferrin, dexamethasone, ascorbic acid for
chondrogenic differentiation; insulin, transferrin and selenium for skeletal
myogenic differentiation; dexamethasone, ascorbic acid and β-glycerophosphate
for osteogenic differentiation (Fig. 1.6) (100-105). Therefore, from a common
MSC population in the mesoderm, receiving different extrinsic stimuli can initiate
differentiation towards specific cell type by triggering a tissue specific
transcription factor, as SOX5/6/9 for chondrocytes, PPARγ for adipocytes, MyoD
family for myoblasts, and RUNX2/Osterix for osteoblasts (106).

1.5.2. Osteogenic differentiation
Bone tissue is a calcified connective tissue derived from the mesodermal lineage
of the developing embryo. Osteoblasts, the mononucleated bone forming cells,
are of a mesenchymal origin responsible for synthesis and mineralization of bone
tissue initially at the forming stage and later at remodeling of the skeletal bone
structure (107). During in vitro osteogenic differentiation, MSCs follow the
intramembranous ossification mode starting by condensation of the stem cell
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Figure 1.6. MSCs are multipotent in vitro and differentiate towards all three
germ layer lineages. Mesenchymal stem cells including PMSCs are able to selfrenew and differentiate towards all three germ layer lineages of ectoderm,
mesoderm and endoderm. Transdifferentiation of MSCs in vivo is still
controversial, but it has been achieved in vitro with different stimulation factor
combinations which may not be present in the natural MSC niche in vivo.
Reproduced from Nature Reviews Immunology 8(9), Uccelli A, Moretta L and
Pistoia V. Mesenchymal stem cells in health and disease. Page 727 Copyright
2008, with permission from Nature Publishing Group.
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population and direct differentiation into osteoblasts, without the need of
cartilaginous template for ossification (108). Osteogenic differentiation has three
phases: proliferation and condensation, extracellular matrix secretion and
maturation, and matrix mineralization (109). The initiation of osteoblast formation
is controlled by RUNX2, a lineage-specific transcription factor responsible for
directing the multipotent MSC towards the osteoblast lineage (110). RUNX2
expression is essential for MSC proliferation and condensation with the highest
expression just prior to differentiation; RUNX2 can inhibit differentiation if its level
remains high (110-112). The lack of RUNX2 in mice causes bone malformation
due to the absence of osteoblasts and death shortly after birth due to breathing
dysfunction; also the lack of RUNX2 is manifested in human disease known as
cleidocranial dysplasia (110, 112). Another known lineage-determining factor,
Osterix, is downstream of RUNX2 and is also required for complete commitment
of progenitor cells towards the osteoblast differentiation (113). At the early stage
of

osteoblast

differentiation,

RUNX2

is

responsible

for

transcriptional

upregulation of matrix deposition proteins (type I collagen, osteopontin, bone
sialoprotein and osteocalcin), but is not essential to maintain these proteins in
mature osteoblasts (107, 110, 112). During osteoblast maturation, higher
expression of both RUNX2 and osteopontin higher expression is a marker of
immature osteoblasts, whereas the upregulation of osteocalcin marks mature
osteoblast with a loss of RUNX2 and osteopontin expression (114).
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1.5.3. Role of low oxygen tension and IGFs in osteogenic differentiation
In a low oxygen tension microenvironment, osteogenic differentiation is severely
inhibited with reduced matrix maturation and mineralization starting at an early
stage, thereby keeping the cells in a stem cell like state (115). This inhibition is
mediated by HIF-1α, under low oxygen tension or if stabilized in room air, to
reduce RUNX2 expression and alkaline phosphatase activity and delay matrix
production and mineralization (115, 116). However, stem cell preconditioning in
low oxygen tension has shown an improved state of osteogenic differentiation. In
their natural microenvironment, undifferentiated stem cells are in a steady
dormant state with a low energy demand that is mostly dependent on glycolysis,
with very low aerobic respiration and mitochondria count, even in room air
conditions (117). On the other hand, osteogenic differentiation goes through
several high energy demanding processes including matrix production,
maturation and mineralization (115). Indeed, differentiating osteoblasts undergo
a metabolic switch from anaerobic glycolysis to aerobic mitochondrial respiration
that is inhibited under low oxygen tension (116). Generally, a metabolic switch is
achieved by decreasing glycolysis enzymes and lactic acid production,
upregulation of mitochondrial biogenesis and ATP production, and upregulation
of antioxidant enzymes to eliminate reactive oxygen species (118, 119). By
mathematical modeling, an oxygen gradient exists in the bone marrow where the
most primitive stem cells are located in a very low oxygen tension
microenvironment far from a bone marrow sinus (120), which suggests that
differentiating MSCs move towards higher oxygen tension upon osteoblast
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differentiation. Therefore, low oxygen tension can maintain stem cells in a higher
multipotent proliferative state and inhibit differentiation via hypoxic molecular
signaling and low energy supply that does not support the metabolic demand for
a mature differentiated state.

In vitro, osteogenic differentiation is triggered by the combined signaling of 100
nM dexamethasone, 50 µM ascorbic acid followed by 10 mM β-glycerophosphate
in presence of 10% fetal bovine serum (121). However, optimization experiments
using lower concentration of dexamethasone (5-10 nM) and a higher
concentration of ascorbic acid (150-250 µM) achieved a higher level of
osteogenic differentiation that was significantly improved in presence of human
serum or a defined xeno-free media — supplemented with specific growth factors
such as insulin, FGF and activin A (121). Therefore, optimization of differentiation
conditions can be achieved by changing the growth factor composition in the
microenvironment. In immediate contact with bone cells in vivo, several growth
factors, hormones and cytokines (BMPs, sonic hedgehog proteins, Wnt/βcatenin,

FGF

and

IGF)

mediate

osteoblast

commitment,

growth

and

differentiation (107). IGFs (IGF-I and IGF-II) secreted by skeletal bone cells play
an important role in paracrine/autocrine stimulation of bone formation, growth,
and metabolism (122, 123). In osteoblast primary cultures, one of IGF-I functions
is to exert an anti-apoptotic action and promote survival of differentiating
osteoblasts especially at later stages (123). Also, IGF-I was shown to play a
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chemotactic role that stimulates the recruitment and migration of osteoblasts
(124). Local overexpression of IGF-I in osteoblasts is shown to accelerate the
rate of bone formation and increase the pace for matrix mineralization (125). The
function of IGF-I signaling is mediated via the IGF-IR, which upon its deletion
caused a failure to mineralize bone matrix (125). In disease conditions such as
osteoporosis, primary osteoblast cultures has an impaired IGF-IR signaling
decoupled from IGF-I stimulation, which possibly causes lower proliferation rate
and differentiation and therefore bone loss (126). Therefore, IGF has no effect on
osteoblast commitment (no change in RUNX2 expression), but enhances cell
maturation at later stages for matrix secretion (increased type-I collagen) and
mineralization (127).

1.6. Scope of Thesis
1.6.1. Tissue regenerative therapy – stem cell promise
In the twenty first century, the burden of organ failure and degenerative diseases,
which cannot be corrected by drugs alone, has been focused on the promise in
cell replacement therapy and tissue regeneration (128). Some of the diseases
that are targeted by stem cell therapy include hormonal dysfunction (diabetes
and growth hormone), neurodegenerative diseases (Parkinson’s, Alzheimer’s
and Huntington’s) and cardiovascular diseases (myocardial infarction, peripheral
vascular ischemia) as well as various injuries in the cornea, skeletal muscle, skin,
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joints and bones (129). In this context, stem cells have a great potential for
tissue/organ repair, replacement of dying cells and promoting the survival of
damaged tissue (130). However, the specific use of stem cells from the sources
available has their own risks and limitations that can restrict their use for tissue
regeneration. ESCs, in principle, can be used to generate any cell type from the
three germ layers; however, the uncertain result of tumorigenicity potential and
the ethical and political controversies converge to an obstacle for successful use
(128). To date, one clinical trial is ongoing to test the use of ESC in spinal cord
injury (131). In line with pluripotent ESCs, iPSCs have the advantage of being
generated from autologous sources that can eliminate graft versus host disease;
however, they are not ready for clinical trials due to the lack of understanding of
the optimal reprogramming effect on cells behavior in vitro and optimally for in
vivo application. MSCs so far, show great promise as they have less ethical
controversies and less tumorigenicity (do not form teratomas in vivo) due to less
proliferative potential and a more restricted lineage differentiation. Also, MSCs
have the immunomodulatory effect to reduce an immune response and were able
to engraft successfully in a therapy resistant graft versus host disease patients
(130). Among the adult MSC populations described to date, only the
hematopoietic stem cells, isolated from bone marrow and umbilical cord blood,
have been used in over 1,200 active open trials (128, 132). More trials are testing
other sources of stem cells for clinical intervention, with 3 embryonic-, 36
adipose-, 280 neural- stem cells and 115 using MSCs (128). In Canada, there
are 204 open or pending clinical trials using stem cells, as listed on the NIH
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website clinicaltrials.gov (128). Therefore, research is still ongoing to optimize the
use of MSCs from alternative sources for tissue regeneration therapies.

1.6.2. Hypothesis and objectives
In this study, we aim to obtain a homogeneous multipotent stem cell population
from different gestations of the human placenta (PMSCs), optimize cell culture
conditions and manipulate the stem cell fate to induce cell differentiation in vitro.
By manipulating the stem cell microenvironment, my objective is to characterize
the role of IGF-I and -II, abundant growth factors in the placenta, to regulate
PMSC fate under physiological low oxygen tension by investigating, i) the
signaling pathways that promote stem cell multipotency and proliferation and ii)
the differentiation commitment of PMSCs towards osteogenic progenitor cells.

The central hypothesis is that the interactive signaling between IGFs and oxygen
tension is required to alter gestational stage dependent PMSC fate towards selfrenewal or differentiation.
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The effect of low oxygen tension on IGF signaling in PMSC is investigated as
follows:
1. To characterize the role of IGF-I on early and late gestation PMSCs
multipotency and proliferation and the signaling cascade governed by
ERK/2 and the AKT signaling pathways in low oxygen tension conditions
(Chapter 2).
2. To compare and contrast the role of IGF-I and IGF-II in maintaining PMSC
multipotency, proliferation and signaling in low oxygen tension conditions
(Chapter 3).
3. To determine the role of IGFs on PMSC commitment and differentiation
towards the mesodermal osteogenic lineage (Chapter 4).
In this study, we showed that the placenta is an abundant source of multipotent
mesenchymal stem cells and that the physiological microenvironment is crucial
for directing the stem cell fate to maintain multipotency or differentiation. This
work is an antecedent investigation in understanding the niche conditions
required to determine the specific fate of stem cells that will lead to improved
success in tissue regenerative therapies.
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CHAPTER TWO
Low Oxygen Tension and Insulin-like Growth Factor-I (IGF-I) Promote
Proliferation and Multipotency of Placental Mesenchymal Stem Cells
(PMSCs) from Different Gestations via Distinct Signaling Pathways

A version of this chapter has been revised following reviewers comments and
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2.1.

INTRODUCTION

Human placenta is a readily available source of adult stem cells, termed
placental mesenchymal stem cells (PMSCs) that originate from the primitive
allantoic mesenchyme derived from the embryoblast (1). Stem cells have been
isolated from different parts of the placenta (chorionic villi, membranes, umbilical
cord, chorioallantois and amniotic fluid) and the largest source is the chorionic
villi (2, 3). Studies have shown that PMSCs are multipotent, can differentiate into
cells of all three germ layers including cartilage, bone, endothelial, adipose,
muscle or neuronal lineages, express embryonic stem cell markers such as
OCT4, SSEA-4, TRA-1-61, TRA-1-80, and are devoid of trophoblastic and
hematopoietic markers (4-7). PMSCs are potential candidates for regenerative
therapy and tissue engineering, as they have significantly less or no allo- or
xenogeneic immune response, and suppress alloreactive T cells in a mixed
lymphocyte reaction (8, 9).

The stem cell microenvironment or niche maintains normal pluripotent capacity
and enables cells to respond appropriately to cues when regeneration is needed.
Abnormalities in this capacity can lead to disease states such as tumorigenesis
or an opposite outcome, poor healing. During normal human pregnancy, the
microenvironment of the developing placenta undergoes changes in oxygen
tension and growth factor concentrations. IGF-I concentration is low at early
gestation and increases at term to reach ~100 ng/mL in the umbilical cord
venous blood (10). Similarly, oxygen tension is very low at implantation, near 0%,
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reaches 2.4% O2 at first trimester and increases gradually after the formation of
the utero-placental circulation to reach ~5 - 8% O2 similar to adjacent
endometrium (11, 12). Hence, PMSCs isolated from early and late gestational
stages may have different responses to IGF-I and low oxygen tension mimicking
their natural microenvironment.

Insulin-like growth factors (IGFs; IGF-I and -II) are major autocrine/paracrine
growth factors that regulate growth and differentiation during development of all
tissues including placenta, and they are expressed as early as in preimplantation
embryos in humans (13, 14). Circulating levels of IGF-I and -II correlate with
placental and fetal weights, where both can regulate cell growth, differentiation
and cell-fate changes through several mitogen activation cascades mainly
through the IGF-I receptor (IGF-IR), a receptor tyrosine-kinase (15-17). Upon
ligand binding, IGF-IR initiates mitogenic and metabolic signals by activating the
two main signaling transduction pathways: the phosphoinositide 3-kinase (PI3K)/AKT/PKB and the extracellular signal-regulated kinase (ERK1/2) (18, 19). In
certain niche conditions, these molecules can induce transcriptional activity that
would promote growth, differentiation, survival or self-renewal (20, 21). However,
little is known about signaling mechanisms underlying IGF-I actions on MSC
proliferation and fate changes.

Oxygen tension plays a major role in stem cell proliferation and differentiation,
especially in the placenta. It was shown that cytotrophoblasts proliferate in low
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oxygen tension (2% O2), while they differentiate in high oxygen tension (20% O 2)
(11). Also, low oxygen tension can retard the differentiation process of
mesenchymal/progenitor stem cells into adipose and cartilage forming cells
through changes in hypoxia inducible factor-1 (HIF-1) signaling (22-24). Under
low oxygen tension, HIF-1α, the oxygen-sensitive α-monomer of the HIF-1, is
stabilized and prevented from ubiquitination and proteosomal degradation (25,
26). HIF-1 can induce transcription of at least 70 genes containing functional
hypoxia responsive element (HRE). However, it has been estimated that more
than 200 genes and up to 5% of the human genes, depending on the cell-type,
are induced by hypoxia, via HIF-1, but not necessarily all are regulated through
HRE regions (27-29). HIF-1 can target major genes of diverse functions including
cell surface receptors, angiogenic growth factors, glucose transporters, and
glycolytic enzymes that primarily promote cell survival (25, 30). Interestingly,
downstream of IGF-I signaling, p-ERK1/2 phosphorylates HIF-1α to increase its
stability under room air by inhibiting its proteosomal degradation, thereby
inducing transcription from HRE containing promoters (31, 32). Low oxygen
tension is required to maintain stem cell pluripotency by HIF-2 interaction with the
OCT4 promoter region to induce increased transcriptional activity (33). OCT4 is
the master regulator of pluripotency in ESCs and is indispensible to generate
iPSCs, and is lost upon differentiation (34-38).

To determine the developmental changes and signaling differences in the
presence of IGF-I and low oxygen tension, we used both Preterm (P-) and Term
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(T-) PMSCs to assess their role in determining stem cell proliferation and
multipotency. We show here that the pattern of the IGF-IR, IRS-1, ERK1/2 and
AKT levels and phosphorylation are gestational stage-dependent and are
modulated by low oxygen tension. We conclude that IGF-I signaling is dependent
on oxygen tension, and that the balance between the two factors regulates OCT4
levels, which is a marker for stem cell pluripotency.

2.2.

MATERIAL AND METHODS

2.2.1. PMSC Isolation and Characterization
PMSCs were isolated from human placentae of two gestational ages, Preterm
PMSCs from 10-13 weeks and Term PMSCs from 37-42 weeks (at least three
PMSC primary cell populations from each gestational age). After informed
consent, preterm placentae were collected from patients who underwent
therapeutic pregnancy termination, and term placentae from healthy pregnant
women who underwent elective Cesarean section. Immediately after surgery,
small pieces of chorionic villi were dissected free of maternal decidua. Tissue
samples were minced mechanically and enzymatically digested with collagenase
IV/hyaluronidase and DNase I, followed by trypsin/EDTA for 20 min at 37ºC,
followed by 10 min wash at 4ºC in 10% fetal bovine serum (FBS) in PBS (Gibco,
Mississauga, ON). Cells were passed through a nylon tissue mesh (45 μm) to
obtain a single cell suspension. Next, cells were separated on a Percoll (Sigma)
discontinuous gradient (layers 4 and 5) modified from Worton et al. for
hematopoietic stem cell isolation (39), and then seeded in tissue culture flask
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(Falcon) using DMEM/F12 media (Gibco, Mississauga, ON) containing 10% FBS
and antibiotic-antimycotic solution. After 4 days, media was changed and nonadherent cells were washed to leave behind adherent PMSCs able to form
colonies.

Placental MSCs were characterized as mentioned previously (40-42), by flow
cytometry for the absence of hematopoietic markers CD45 and CD34, and for
cytokeratins (-8, -9, and -17), and the presence of MSC markers CD105 (SH2)
and CD73 (SH3, SH4), and CD117 (c-Kit, stem cell factor receptor). In short, cell
monolayer was trypsinzied by 1X TrypLE Express (Gibco, Mississauga, ON) for 5
min and centrifuged at 1000 rpm. Cell pellet was resuspended in 1x DPBS
(Gibco, Mississauga, ON) and incubated with the primary Ab for 1-hr at 37° C,
followed by Alexafluor 488 secondary Ab (A11029, Invitrogen) for 30 min at 37°
C. Cells were then washed and resuspended in 1 mL of 1x DPBS and run using
Beckman Coulter flow-cytometer reaching 10,000 counts.
By immunoblotting, PMSCs were positive for pluripotency markers OCT4, SOX2
and NANOG. Also, PMSCs were able to differentiate towards osteogenic,
endothelial, adipose and muscle lineages from mesodermal lineage and neuronlike cells expressing Nestin from the ectodermal lineage.

2.2.2. Cell Culture and Incubation in Low Oxygen Tension
For each experiment, two preterm or term PMSC populations were used in
triplicate. Cells were cultured and maintained using DMEM/F12 media with 10%
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FBS and FGF-2 (100 ng/mL) (Gibco, Mississauga, ON). Before treatment, cells
were cultured in DMEM/F12 with 10% FBS for 24-hrs. Upon treatment, PMSCs
were switched directly to fresh serum free media containing IGF-I (0 – 100
ng/mL) in the presence or absence of either 5 μM U0126 or 10 μM LY294002
(Cell Signaling Tech., Danvers, MA). Proliferation was measured using the WST1
reagent assay (Roche) following manufacturer’s protocol. PMSCs were seeded
at 5,000 cells/100 µL in 96-well plates. All cell cultures were then placed in either
a 5% CO2 incubator or a hypoxia chamber—filled with a 1% O2, 5% CO2,
balanced N2 gas mixture (BOC Canada Ltd, Toronto, ON) for 15 min to ensure
saturation. The saturation of the oxygen in the chamber was measured using a
Hudson 5590 Oxygen Monitor (Hudson, Ventronics Division). Thereafter, the
chamber was placed in a tissue-culture incubator at 37o C. At the end of the
experiment, oxygen tension in culture media was measured using the ABL700
series blood gas analyzer (Radiometer, Copenhagen, Denmark).

2.2.3. Human Phospho-kinase Array
To screen for kinases phosphorylated upon IGF-I stimulation under room air or
low oxygen tension, PMSCs were serum-deprived for 24-hrs under 20% or 1%
oxygen. For IGF-I treatment, PMSCs from both oxygen tension conditions were
washed with 1x PBS (x 3) and then stimulated with 100 ng/mL of IGF-I for 15
min., a proteome ProfilerTM Array (#ARY003, R&D system, Minneapolis, MN)
Part A was used according to manufacturer’s protocol. Treated cells were rinsed
with PBS and then solubilized in lysis buffer and the protein concentration was
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determined by Bradford Assay (BioRad laboratories, Hercules, CA). Kinase array
was incubated with cell lysate of the same protein concentration, washed, and
specific kinases phosphorylated were identified by detection biotinylated antibody
cocktail A. Immunocomplexes were detected with a streptavidin-HRP binding and
the signal was developed using enhanced chemiluminescence (ECL) according
to the manufacturer’s instructions (Perkin Elmer Life Sciences), and documented
on Kodak Biomax film (Rochester, NY, USA).

2.2.4. Immunoblotting
Cell lysates were prepared using 1x cell lysis buffer for phospho-proteins
according to manufacturer protocol (#9803, Cell Signaling Technologies,
Burlington, ON, CAN). Protein samples (10-20 μg) were resolved by SDS-PAGE,
and then transferred onto PVDF membranes (Millipore, Bedford, MA). The
membranes were blocked with 5% non-fat-dry milk in 1x TBS (Tris-buffered
saline) for 1 hr at room temperature. Blots were then washed in 1x TBS 0.1%
Tween 20 (TBS-T) (3x for 5 min) followed by incubation at 4 oC overnight with
primary antibodies as per manufacturers’ protocols. Blots were then washed
using TBS-T (3x for 10 min) and were incubated with secondary HRP-labelled
antibody for 1 hr at RT. Immunocomplexes were detected by ECL and detected
using VersaDOCTM Imaging System (Bio-Rad).
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2.2.5. Antibodies
For flow cytometry, the following antibodies were used: CD-73 (#550256) (BD
Pharmingen, San Jose, CA), PE conjugated CD105 (#12-1057-73) (eBioscience,
San Diego, CA) CD-117/c-Kit (sc-13508) (Santa Cruz Biotech., Santa Cruz, CA).
To detect the IGF-I activated signaling molecules, the following antibodies were
used: phospho-p44/42 MAPK (#4377), p44/42 MAPK (#9102) phospho-AKT
(Ser473, #4051), AKT (#9272), PCNA (PC10, #2586), and IRS-1 (#2382) from
Cell Signaling Technologies (Danvers, MA, USA). For OCT3/4, antibody (N-19,
sc-8628) (Santa Cruz Biotech., Santa Cruz, CA, USA) was used. For the
detection of hypoxia markers, HIF-1 alpha antibody (H206, sc-10790) (Santa
Cruz Biotech., Santa Cruz, CA, USA) was used. For loading control, pan-Actin
Ab-5 (#MS-1295) (Thermo Fisher Scientific, Fremont, CA) was used. The
secondary antibodies used for immunoblotting were goat anti-rabbit (#170-6515)
or anti-mouse (#170-6516) HRP conjugated antibodies (BioRad laboratories,
Hercules, CA) or donkey anti-goat antibody (sc-2020) Santa Cruz Biotech., Santa
Cruz, CA, USA).

2.2.6. Statistical Analysis
All experiments were run in triplicates from three independent experiments each;
whenever possible, three or more PMSC primary lines were used from each
gestational stage. All graphs and analyses were generated using GraphPad
Prism Software 5.0 (GraphPad Software, San Diego, CA). A Two-way ANOVA
with Bonferroni post hoc test was used for the PMSC WST1 proliferation assay
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and densitometry quantifications. Data are expressed as mean ± standard error
of the mean (SEM); values were considered significant when p<0.05.

2.3.

RESULTS

2.3.1. IGF-I mediated PMSC proliferation response is dependent on oxygen
tension and gestational age
In PMSC cultures, low oxygen tension (1% O2) achieved 52.2 mmHg oxygen
tension in the culture media. This oxygen tension is physiological during human
pregnancy at 12-13 weeks (early second trimester), which ranges between 46.5
mm Hg at the endometrium (maternal side) to 60.7 mm Hg in the placenta (fetal
side) (12). This low oxygen tension stabilized HIF-1α confirming the hypoxic
condition (Fig. 2.1A) and increased OCT4 levels in both types of PMSCs
confirming enhanced multipotency (Fig. 2.1B). Low oxygen tension had no effect
on the expression of surface markers (CD73, CD105 and CD117/c-kit) in both Pand T-PMSCs (Fig. 2.1C). However, gestational age differences were detectable
between the two PMSCs, higher abundance of OCT4 in room air (one-way
ANOVA, p<0.05) and higher CD117/c-kit expression (~15-fold) in P-PMSCs than
in T-PMSCs.
To demonstrate the effect of IGF-I on PMSC proliferation, we subjected P- and TPMSCs to increasing concentrations of IGF-I and low oxygen tension. P-PMSCs
exhibited continued proliferation in serum-free media, which was increased in a
dose-dependent manner by addition of IGF-I (plateau at 50 ng/mL) (Fig. 2.2A).

57

120-

Room-air

+ COLCl2

10%

0%

+ COLCl2

10%

0%

HIF-1α 42β-Actin 50-

CD105

80
40
0

20%
1%
Oxygen Levels

120
80
40
0

20%
1%
Oxygen Levels

Fold change

CD117
Events (%)

120

Events (%)

Events (%)

CD73

1.23

C

0.47

1.0

50-

OCT4
β-Actin

1.28

FBS

Low-oxygen

Pre-term Term

Room-air Low-oxygen

Room-air

B

Low-oxygen

A

40
*

*

20
0

Pre-term
Term

20%
1%
Oxygen Levels

FIGURE 2.1. Low oxygen tension increases OCT4 levels in PMSCs and
maintaining stemness. (A) HIF-1α levels in P-PMSCs in10% fetal bovine
serum (FBS) in room air or low oxygen tension at 48 hrs (T-PMSCs show similar
levels). The positive control is PMSCs in 10% FBS treated with 0.1 mM cobalt
chloride in room air. β-Actin levels indicate equivalent protein loading. (B) OCT4
levels in P- and T-PMSCs in 10% FBS cultured in room air or low oxygen tension
for 48 hrs. β-Actin levels indicate equivalent protein loading. (C) Stem cell
surface markers (CD73, CD105, CD117) of P- and T-PMSCs in 10% FBS in
room air or low oxygen tension expressed as % of total positive cells (measured
in 10,000 cells, n=3; one-way ANOVA, p<0.05, * = significant difference between
low oxygen and room air). Low oxygen tension increased OCT4 levels in preterm
and term PMSCs. Stem cell surface marker expression was not changed by low
oxygen tension in preterm or term PMSCs.
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However, low oxygen tension together with IGF-I (100 ng/mL) further increased
P-PMSC proliferation (Fig. 2.2A). On the other hand, T-PMSCs had not
significantly increased proliferation in response to IGF-I in room air that was
further increased by low oxygen tension (highest at 10 ng/mL and decreased at
higher concentrations) (Fig. 2.2B). Since the proliferation of P-PMSCs and TPMSCs in low oxygen tension was noticeably different at 100 ng/mL of IGF-I, a
time course experiment (over 12, 24 and 48-hrs) was conducted. In room air,
PMSC proliferation was significantly increased by IGF-I in both P- and T-PMSCs
after 24-hrs (3.5-fold and 2.5-fold, respectively) (t-test, P = 0.0005) (Fig. 2.2C and
D). Low oxygen tension enhanced the IGF-I stimulated proliferation of both
PMSCs (up to 4.6-fold in P-PMSCs compared with 3.1-fold in T-PMSCs) (t-test,
P = 0.0001). However, at 48-hrs, the proliferation subsided in both P-PMSCs and
T-PMSCs to ~ 0.5-fold in both oxygen tensions (Fig. 2.2C and D). Overall, the
response to IGF-I was gestational age-dependent and enhanced by low oxygen
tension—P-PMSCs having a higher proliferation response.

2.3.2. IGF-I mediated PMSC OCT4 expression is dependent on oxygen
tension and gestational age
Similar to the proliferation response, we checked for multipotency regulation by
IGF-I concentration and exposure time in low oxygen tension. In P-PMSCs, IGF-I
(100 ng/mL) increased OCT4 levels, in both oxygen tension conditions (Fig.
2.3A), whereas in T-PMSCs, OCT4 only increased in response to IGF-I in room
air (Fig. 2.3B). OCT4 was also temporally regulated; in P-PMSCs
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FIGURE 2.2. Low oxygen tension increased PMSC proliferation in response
to IGF-I. PMSC proliferation was assessed using the WST-1 colorimetric
proliferation assay using absorbance at 450 nm with a background reference of
650 nm. (A) P-PMSCs and (B) T-PMSCs were treated with increasing
concentration of IGF-I concentrations (0, 10, 50 and 100 ng/mL) in room air or
low oxygen tension for 48-hrs. (C) P-PMSCs and (D) T-PMSCs were treated with
IGF-I (100 ng/mL) under room air or low oxygen tension in a time course from 0
to 48-hrs. Two-Way ANOVA, P<0.05, n=8; a = significant difference between
room air and low oxygen tension, * = significant difference by different IGF-I
concentration. A cell counting experiment has been done as shown in Figure
S2.1A and B. In both P- and T-PMSCs, low oxygen tension enhanced the effect
of IGF-I on cellular proliferation.
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under room air, IGF-I gradually increased OCT4 levels that peaked at 12-hrs,
and was stable up to 48-hrs (Fig. 2.3C). Low oxygen tension induced a similar
expression pattern with a maximal increase at 24-hrs. In T-PMSCs, OCT4
expression increased rapidly after IGF-I exposure in room air, but not in low
oxygen tension (Fig. 2.3D). The maximal increase in OCT4 expression (up to
1.5-fold) occurred earlier in T-PMSCs (6-hrs) compared with P-PMSCs (12 hrs)
suggesting that IGF-I effect is gestational age-dependent—increased sensitivity
in T-PMSCs.

2.3.3. ERK1/2 and AKT signaling downstream of IGF-IR
To map the downstream effectors of IGF-I signaling, we used a phospho-kinase
array (Fig. 2.4A). Short-term exposure of P-PMSCs (15 min) in room air to IGF-I
increased phosphorylation of ERK1/2 (spots A5, A6) (Fig. 2.4B). Increased pERK1/2 by low oxygen tension was not increased further by IGF-I (Fig. 2.4B).
AKT phosphorylation (spots B9, B10) was increased by IGF-I in both room air
and low oxygen tension conditions (Fig. 2.4B). Similarly, IGF-I increased pERK1/2 in room air, and low oxygen tension increased the phosphorylation
independent of IGF-I (Fig. 2.4C and D). In addition, p-AKT was dependent on
IGF-I for phosphorylation and was less so by low oxygen tension (Fig. 2.4C and
D). The change in signaling proteins was not associated with changes in IGF-IR
or in OCT4 levels (Fig. 2.4C). Overall, IGF-I increased ERK1/2 phosphorylation
under room air and less under low oxygen tension, which was already induced
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FIGURE 2.3. OCT4 levels in PMSCs in response to IGF-I and low oxygen
tension. Levels of OCT4 were quantified by densitometry of immunoblots in PPMSCs and T-PMSCs. (A) P- and (B) T-PMSCs were stimulated with increasing
concentration (0, 10, 50 and 100 ng/mL) of IGF-I for 48-hrs under room air or low
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independent of IGF-I; however, IGF-I was required for AKT phosphorylation
under both oxygen tensions.

2.3.4. Phosphorylation of AKT and ERK1/2 is IGF-I-concentration and
exposure-time dependent
IGF-I or low oxygen tension stimulated ERK1/2 phosphorylation in both types of
PMSCs; however, low oxygen tension reduced levels of the IGF-I mediated
increase (Fig. S2.1C). p-ERK1/2 levels in P-PMSCs were unchanged with
increasing concentrations of IGF-I in room air but decreased slightly under low
oxygen tension (Fig. 2.5A). In T-PMSCs, ERK1/2 phosphorylation was increased
by IGF-I in a dose-dependent manner (p<0.01, Pearson r =0.993) in room air
(Fig. 2.5A, right), whereas the opposite was observed in low oxygen tension
(p<0.05, Pearson r = -0.953). The phosphorylation pattern of ERK1/2 was time
dependent, in P-PMSCs, the maximal increase in p-ERK1/2 occurred 1-hr after
IGF-I stimulation under low oxygen tension (two-fold higher than in room air), and
declined at 6-hrs (Fig. 2.5B, left). p-ERK1/2 levels increased again after 48-hrs if
cells were maintained in low oxygen conditions (Fig. 2.5B, left). In T-PMSCs, pERK1/2 levels were similar to P-PMSCs but at higher levels demonstrating a
greater IGF-I response (Fig. 2.5B, right).

Unlike p-ERK1/2, AKT phosphorylation was increased only by IGF-I especially
under low oxygen tension in both types of PMSCs (Fig. 2.5C, left). p-AKT
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reached its maximal activation at 100 ng/mL IGF-I in P-PMSCs, and at 50 ng/mL
in T-PMSCs, again showing sensitivity of T-PMSCs (Fig. 2.5C). Under room air,
AKT phosphorylation was significantly higher in T-PMSCs, whereas the effect of
low oxygen tension was observed predominantly in P-PMSCs. These results
demonstrate a predominant effect of IGF-I on AKT activation compared to
ERK1/2 under low oxygen. Concurrently, maximal AKT phosphorylation level
was achieved at 15-60 min post IGF-I exposure in both PMSCs under room air
(Fig. 2.5D). Low oxygen maintained higher levels of p-AKT, especially in PPMSCs, before reaching its lowest level at 48-hrs (Fig. 2.5D).

Thus, in low oxygen tension, we observed a correlation between IGF-I mediated
increase of OCT4 levels with a decrease in p-ERK1/2 and an increase in p-AKT.
This can also be temporally regulated by the increased p-AKT and decreased pERK1/2, especially seen in low oxygen tension in P-PMSCs. Therefore, IGF-I
concentration and stimulation time control the signaling via p-ERK1/2 and p-AKT,
which may directly correlate with multipotency and proliferation.
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FIGURE 2.5. Oxygen tension modulates p-ERK1/2 and p-AKT in PMSCs in
response to IGF-I concentration and exposure time. Phosphorylation of (A
and B) ERK1/2 and (C and D) AKT were quantified by densitometry of
immunoblots of P-PMSCs and T-PMSCs cell lysates. P- and T-PMSCs were
stimulated with increasing concentration (0, 10, 50 and 100 ng/mL) of IGF-I for
48-hrs or with IGF-I (100 ng/mL) over time 0-48-hrs under room air or low oxygen
tension. Quantification by densitometry was normalized to the respective total
kinase, β-Actin for protein load and DNA content to account for stem cell
heterogeneity. Two-Way ANOVA, P<0.001, n=3, a = significant difference
between room air and low oxygen tension; * = significant difference by different
concentrations of IGF-I or stimulation time. IGF-I increased phosphorylation of
ERK1/2 and AKT in both P- and T-PMSCs. Both ERK1/2 and AKT increased
rapidly within 1 hr. p-ERK1/2 decreased acutely, whereas p-AKT response was
more prolonged. Low oxygen tension prolonged ERK1/2 and AKT
phosphorylation.
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2.3.5. IGF-IR and IRS-1 levels and phosphorylation are modulated by
oxygen tension and IGF-I concentration and stimulation time
IGF-I signaling starts at the level of the receptor, IGF-IR. As a result, levels of
IGF-IRα, the IGF-I binding extracellular subunit, were increased in serum free
conditions, and decreased by IGF-I in a dose-dependent manner in both P- and
T-PMSCs (Fig. 2.6A). In low oxygen tension, IGF-IRα was maintained higher
even in presence of IGF-I (Fig 2.6A). Also, IGF-IRα was decreased upon
increased stimulation time by IGF-I (Fig. 2.6B). However, low oxygen tension
maintained a more stable level of IGF-IRα in both P- and T-PMSCs than the
sharp decrease by 48-hrs in room air. IGF-IRβ phosphorylation was also
manipulated by low oxygen tension in PMSCs (Fig. S2.3). Levels of p-IGF-IRβ
were increased with increasing concentration of IGF-I (Fig. S2.3 A and B), with a
higher phosphorylation in P-PMSCs in low oxygen tension. However, increasing
the stimulation time decreased IGF-IRβ phosphorylation with a more stable level
in low oxygen tension (Fig. S2.3 C and D).

The signaling pathway via p-ERK1/2 or p-AKT is dependent on interacting
adaptor molecules with the IGF-IR. IRS-1, a major interacting adaptor protein
with p-IGF-IRβ, was not changed by increasing IGF-I concentration in P-PMSCs,
whereas was increased in T-PMSCs in room air (Fig 2.6C). Low oxygen tension
maintained higher IRS-1 levels independent of IGF-I in both PMSCs (Fig. 2.6C).
IRS-1 levels were also dependent on the duration of IGF-I exposure time, which
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FIGURE 2.6. Oxygen tension modulates IGF-IRα and IRS-1 levels in PMSCs
in response to IGF-I concentration and exposure time. Levels of (A and B)
IGF-IRα and (C and D) IRS-1 were quantified by densitometry of immunoblots in
P-PMSCs and T-PMSCs. P- and T-PMSCs were stimulated with an increasing
concentration (10, 50 and 100 ng/mL) of IGF-I for 48-hrs or in presence of IGF-I
(100 ng/mL) over 0-48-hrs under room air or low oxygen tension. Quantification
of immunoblots (presented in Fig. S2.2) by densitometry was normalized to βActin for protein load and DNA content to account for stem cell heterogeneity.
Two-Way ANOVA, P<0.001, n=3, a = significant difference between room air and
low oxygen tension; * = significant difference by different IGF-I concentrations or
stimulation time. Low oxygen tension maintained increased levels of IGF-IR and
IRS-1 that were decreased by IGF-I and exposure time.
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has peaked at 1 hr then decreased (Fig. 2.6D). Low oxygen tension, however,
maintained a narrow decrease in IRS-1 levels.

To understand the role of IRS-1 in IGF-I signaling, we checked two
phosphorylation sites on IRS-1, p-Y896 for GRB2 binding upstream of p-ERK1/2
(43), and p-Y612 for p85 subunit of PI3K upstream of p-AKT (44).
Phosphorylation levels were different between pY612 and pY896. Low oxygen
tension upregulated p-Y896 in P-PMSCs and less in T-PMSCs (Fig. S2.3 A and
B), which correlated with a higher p-ERK1/2 and proliferation. The levels of pY612 were more responsive to increase with IGF-I concentration (Fig. S2.3 A
and B), which are required for the increased p-AKT activation levels seen in
figure 2.5 (C and D). With increased exposure time, p-Y896 was increased
(peaked at 12 and 48 hrs) in both PMSCs, whereas p-Y612 was increased
gradually (a major peak by 12 hrs) but decreased at 48 hrs with a higher level in
P-PMSCs (Fig. S2.3 C and D). These findings indicate that low oxygen tension is
a dominant regulator to increase IGF-IR and IRS-1 and their phosphorylation
levels in presence of IGF-I. These changes may explain the induced
phosphorylation levels seen with p-ERK1/2 and p-AKT levels that correlates with
a higher proliferation and multipotency.
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2.3.6. Inhibition of ERK1/2 and AKT suppresses PMSC proliferation and
OCT4 levels
We inhibited signaling downstream of IRS-1 of either MEK1/2 or PI3K using
U0126 and LY294002. In P-PMSCs, U0126 reduced p-ERK1/2 levels in the
presence of IGF-I (100 ng/mL) (Fig. 2.7A, left), and increased p-AKT levels under
low oxygen tension (Fig. 2.7B, left). LY294002 decreased p-AKT in both oxygen
tension conditions, while IGF-I had no effect (Fig. 2.7D, left). LY294002 is not a
strict inhibitor of PI3K/AKT pathway, because it also reduced the p-ERK1/2 levels
(Fig. 2.7C, left). In T-PMSCs, U0126 had less inhibitory effect than in P-PMSCs
in absence of IGF-I, while the inhibitory effect increased at higher concentrations
of IGF-I (Fig. 2.7A, right). Also, LY294002 increased p-ERK1/2 levels and this
effect was parallel to reduction in p-AKT levels, which were further
downregulated by IGF-I (Fig. 2.7C and D, right).

The physiological role of activating ERK1/2 and AKT in PMSCs was evaluated by
proliferation assay. Both U0126 and LY294002 abolished the IGF-I stimulated
proliferation in both P- and T-PMSCs (Fig. 2.8A and B; C and D, respectively)
that was not due to induced apoptosis (Fig. S2.4). Low oxygen tension increased
cell proliferation in the presence of both inhibitors but did not restore normal
proliferation response by IGF-I (Fig. 2.8 A – D). Interestingly, LY294002 caused a
greater decrease in cell proliferation regardless of IGF-I or oxygen tension (P <
0.0001) (Fig. 2.8C and D). The decreased proliferation by the inhibitors was
greater in presence of IGF-I suggesting that PMSC proliferation is dependent on
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FIGURE 2.7. The effect of upstream MEK1/2 inhibition or PI3K inhibition on
ERK1/2 and AKT phosphorylation PMSCs. (A and C) p-ERK1/2, (B and D) pAKT levels in P-PMSCs and T-PMSCs in the presence of U0126 (5 µM) or
LY294002 (10 µM). Cells were treated with the inhibitor with or without IGF-I (100
ng/mL) under room air or low oxygen tension. Phospho-kinase levels were
normalized to both total level of kinase and to β-Actin. The dotted lines (set at 1)
represent the levels of p-ERK1/2 and p-AKT in DMSO control. The comparison
with DMSO control is present in the supplemental figures (S2.5 and S2.6). TwoWay ANOVA, P<0.001, n=3. U0126 inhibited p-ERK1/2 while increased p-AKT in
presence of IGF-I, especially under low oxygen tension. LY294002 inhibited pAKT and reduced the levels of p-ERK1/2 in presence of IGF-I.
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FIGURE 2.8. Proliferation of P- and T-PMSCs in the presence of ERK1/2 or
AKT pathway inhibitors. Proliferation of both (A and C) P-PMSCs and (B and
D) T-PMSCs is shown by the WST1 assay. P- and T-PMSCs were grown in the
presence of (5 μM) U0126 (A and B) or (10 μM) LY294002 (C and D) in varying
concentrations of IGF-I (0, 10, 50, 100 ng/mL) under room air or low oxygen for
48-hrs. The absorbance was measured at 450 nm with a background reference
of 650 nm. Absorbance values were normalized to their matched DMSO controls.
(Two-way ANOVA, P<0.05, n=8, a = significant difference between room air and
low oxygen tension; * = significant difference by different IGF-I concentrations).
PMSCs were not dying in response of inhibitor as shown in Figure S2.4. U0126
and LY294002 inhibited IGF-I increased P- and T-PMSC proliferation. Lowoxygen tension maintained a higher proliferation but could not rescue inhibition
effect.
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IGF-I signaling via MEK1/2 and PI3K, and eventually through p-ERK1/2 and pAKT. The augmented effect of low oxygen tension on proliferation was
dependent on both signaling pathways.

To determine if p-ERK1/2 and p-AKT are involved in multipotency, OCT4 levels
were measured under low oxygen levels in presence of either U0126 or
LY294002. Blocking p-ERK1/2 pathway did not affect OCT4 levels under low
oxygen tension in both P- and T-PMSCs (Fig 2.9A), while blocking p-AKT
decreased OCT4 levels in the presence of IGF-I (Fig. 2.9B). OCT4 was more
sensitive to PI3K/AKT activation compared to MEK/ERK1/2 and it was restored in
both types of PMSCs when p-AKT level was maintained or increased by U0126
under low oxygen (Fig. 2.7B and 9A). We concluded that p-AKT is important in
maintaining OCT4 expression and therefore multipotency, by IGF-I.

2.4.

DISCUSSION

Unlike Embryonic stem cells (ESCs), MSCs show great promise for tissue
regeneration therapies as they have less ethical controversies and are less
tumorigenic in vivo (45). Also, MSCs have the immunomodulatory effect to
reduce an immune response and to successfully engraft in graft versus host
disease resistant patients (45, 46). However, a large number of MSCs is required
for tissue regeneration therapies; therefore, optimization of in vitro culture
conditions are needed to maintain multipotency
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FIGURE 2.9. The effect of upstream MEK1/2 or PI3K inhibition on OCT4
levels in P- and T-PMSCs in the presence of IGF-I and low oxygen tension.
OCT4 levels from immunoblots of P-PMSCs and T-PMSCs in the presence of (A)
U0126 (5 µM) or (B) LY294002 (10 µM) are shown. P- and T-PMSCs were
treated with the inhibitor with or without IGF-I (100 ng/mL) under room air or low
oxygen tension. OCT4 levels were normalized to total β-Actin levels. The dotted
lines (set at 1) represent the levels of OCT4 in their respective DMSO control.
The comparison with DMSO control is present in the supplemental figures (S2.7).
Two-Way ANOVA, P<0.001, n=3. OCT4 levels were not affected by U0126, but
were reduced by LY294002 especially under low oxygen tension.

76
and proliferation without inducing differentiation. This can be manipulated by
understanding the natural microenvironment of the stem cell niche, which defines
the structural, chemical, and biochemical factors (47, 48). In this study, we
focused on the role of low oxygen tension in controlling the IGF-I mediated
proliferation and multipotency of PMSC from early and term gestation placentae.
Here, we demonstrated that PMSCs from early gestation (P-PMSCs) had a
greater proliferation response to IGF-I and was enhanced by low oxygen tension
(1%) in contrast to term gestation PMSCs (T-PMSCs). IGF-I and low oxygen
major signaling was mediated mainly via p-ERK1/2 and p-AKT. Phosphorylation
of p-AKT but not p-ERK1/2 in low oxygen tension was IGF-I-dependent.
Multipotency, via OCT4 levels, was positively regulated by IGF-I concentration
and stimulation time mainly via the signaling of p-AKT. Thus, IGF-I can mediate
PMSC proliferation and multipotency from different gestations which is enhanced
in low oxygen tension.

Low oxygen tension culture conditions used in this study, which is usually defined
as hypoxia in many in vitro experiments, is the normal physiological oxygen
tension in stem cell niches, whereas room air (20% O2) used for standard cell
culture is hyperoxic. Low oxygen tension found in many tissues ranges from ~
14.4 mm Hg to ~ 68.4 mm Hg (2 - 9% with a mean of 3%) (49-51) and can reach
as low as 7.2 mm Hg (1%) in bone marrow (where hematopoietic stem cells
reside), thymus or the kidney medulla due to atypical blood vessel network (51).
In the placenta, oxygen tension at the endometrial surface starts low at 17.9 mm
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Hg (~ 2.35% O2) prior to the establishment of utero-placental circulation and then
rises up to 60 mm Hg (~ 7.9% O2) after connection with the maternal circulation
(11). We, therefore, proposed that tissue culture conditions should physiologically
mimic in vivo conditions in order to better understand PMSC proliferation and
multipotency.

ESCs exist in low oxygen tension conditions, and fertilization occurs in a hypoxic
microenvironment (12, 52, 53). Culturing embryonic stem cells at low oxygen
(1%) maintained a slower proliferation rate with a higher number of cells in the
inner cell mass (ICM) and, more importantly, maintained greater pluripotency
(higher OCT4 expression and SSEA markers) as compared to those maintained
in ambient room air (51, 54). Therefore, low oxygen tension supports the full
maintenance of pluripotency state of mammalian ESCs. PMSCs are typically
isolated from term pregnancies (55-57); here, we isolated PMSCs from preterm
pregnancies (11-13 weeks) with a hypothesis that P-PMSCs can have a higher
multipotent state. Just like in ESCs, our results showed that low oxygen tension
enhance both proliferation and OCT4 expression in P- and T-PMSCs. However,
P-PMSCs expressed higher levels of OCT4 and proliferate at a higher rate in
response to low oxygen tension compared to T-PMSCs. Hence, P-PMSCs may
have more stemness than T-PMSCs; however, PMSCs from different gestations
have a preserved proliferation and multipotency as tested by self-renewal
markers and differentiation potential into several lineages (bone, adipose,
endothelial and neuronal) (data not shown).
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IGF-I, an important growth factor in mammalian development including the
placenta, stimulates cell mitogenesis, differentiation and survival, primarily via
IGF-IR (16, 58). In the placenta, there is no knowledge of the IGF-I concentration
in the chorionic villi during different gestations; however, IGF-I concentration was
measured at 71 – 132 ng/mL in the umbilical cord blood (10); therefore we used
a concentration between 10 and 100 ng/mL. IGF signaling via the IGF-IR has
been demonstrated to be crucial to mediate ESC multipotency and proliferation
(17). However, the effect of IGF signaling under low oxygen tension conditions is
not understood. Here, in PMSCs, IGF-I increased the proliferation capacity in
both P- and T-PMSCs that was enhanced by low oxygen tension. We monitored
OCT4 level as a marker of multipotency, which was shown to change stem cell
identity when is changed by 50% of the required level for pluripotency (35). In
PMSCs, low oxygen tension alone caused an increase in OCT4 levels compared
to room air (Fig. S1B), while IGF-I alone increased OCT4 levels similar to FBS in
room air (unpublished data). Also, P-PMSCs were less sensitive to increase
OCT4 levels than T-PMSCs (12- vs. 6-hrs) in response to IGF-I compared to TPMSCs, which can be attributed to the already higher OCT4 expression in the
more “naïve” P-PMSCs.

In ESCs, signaling pathways such as RAS/MEK/ERK and PI3K/AKT are
specifically upregulated and are required to confer an undifferentiated state via
maintaining levels of OCT4, SOX2 and NANOG (59). In PMSCs, we identified
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that p-ERK1/2 and p-AKT were the two major kinases activated by both low
oxygen and IGF-I. ERK1/2 is a mitogen kinase that translocates to the nucleus
when phosphorylated to further phosphorylate target genes (c-jun, Elk-1, RSK90,
Myc, MNK, BRF-1, UBF, etc) to promote proliferation or differentiation (60). A
recent discovery of 14 phosphorylation sites on OCT4 has revealed three
putative phosphorylation sites for ERK2 at S111, T118, and S355 (61), which
may play a role to maintain multipotency of stem cells. Also, a chromatin
interaction of ERK2 is shown to be involved in pluripotency transcriptional
machinery to interact with OCT4 promoter region with no clear function (62).
AKT, on the other hand, is responsible for maintaining survival by inhibiting
apoptosis via phosphorylating several targets (c-RAF, BAD, caspase-9, etc.),
promoting cellular growth and protein translation (via mTORC1), and regulating
glycogen synthesis (63). We demonstrated that low oxygen tension alone was
able to intrinsically upregulate the p-ERK1/2 levels (promoting growth), whereas
IGF-I was required for the phosphorylation of AKT (promoting survival)
regardless of the oxygen tension. Also, low oxygen tension caused a global
reduction in p-ERK1/2 levels in presence of IGF-I and a lowered sensitivity to
activate AKT. In P-PMSCs, p-ERK1/2 decreased within a narrow range while, in
T-PMSCs, it decreased in a dose-dependent manner with increasing
concentrations of IGF-I under low oxygen tension. These gestational stagedependent differences in p-ERK1/2 and p-AKT activation patterns suggest that
the maintenance of stemness of PMSCs, which is higher under low oxygen
tension conditions, requires a steady active state of ERK1/2 and AKT signaling.
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P- and T-PMSCs have similar abundance of IGF-IR and IRS-1 levels in response
to IGF-I and low oxygen tension, however, they respond differently to IGF-I as
demonstrated by p-ERK1/2 and p-AKT levels. It was shown previously in 293T,
MEFs, 3T3-L1, and MCF-7 cells that IRS-1 is degraded through a caspasemediated cleavage mechanism, following a transient (1-6 hrs) exposure to low
oxygen (1%) in the presence of IGF-I (64). In PMSCs, low oxygen tension
increased the levels of IGF-IR and IRS-1 in contrast to room air. However, the
longer exposure to IGF-I in low oxygen tension conditions decreased IGF-IR and
IRS-1 to lower levels than room air. This can be a negative feedback mechanism
to downregulate the higher phosphorylation signal at IGF-IRβ and IRS-1 seen in
low oxygen tension. Moreover, phosphorylation of IGF-IRβ in low oxygen tension
was higher in P-PMSCs than T-PMSCs even at higher IGF-I concentration, which
can explain the higher proliferation level at 100 ng/mL. IRS-1 was
phosphorylated at Y896 and Y612 in response to IGF-I, providing docking sites
for upstream signaling cascades for ERK1/2 and AKT activation, respectively.
Low oxygen tension increased higher p-IRS-1 at Y896 and Y612 in P-PMSCs
than in T-PMSCs. This demonstrates that low oxygen tension can mediate an
increased availability of IGF-IR and IRS-1 with more binding sites for p-ERK1/2
and p-AKT signaling, especially in P-PMSCs, which have higher proliferation and
OCT4 levels.
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Inhibition of the activation of ERK1/2 and AKT led to decreased responsiveness
to IGF-I in both P- and T-PMSCs, which was negatively impacted by low oxygen
tension. It has been shown in ESCs that PI3K inhibition leads to differentiation by
reducing OCT4 expression, while MEK1/2 inhibition caused the same effect, but
less prominently (59). In addition, suppression of p-ERK1/2 sustains a basal
state of pluripotency, and therefore conversely, increased p-ERK1/2 levels,
should lead to differentiation (65). These previous findings support our findings in
PMSCs, where we showed that inhibition of PI3K promoted the reduction of
OCT4 levels and cellular proliferation that was greater than the inhibition of
MEK1/2. The PI3K inhibitory effect could not be restored by IGF-I in both types of
PMSCs and low oxygen tension enhanced the effect. As shown in ESCs (59), the
MEK/ERK signaling pathway can potentially be downstream of the PI3K signaling
in PMSCs, as LY294002 also reduced the levels of p-ERK1/2. The inhibition of
MEK/ERK pathway increased p-AKT levels, especially under low oxygen tension
conditions, demonstrating a possible compensatory mechanism for the reduced
levels of p-ERK1/2 necessary to maintain PMSC proliferation and multipotency.
These findings suggest that for the maintenance of multipotency, PMSCs should
be maintained under low oxygen tension with activated PI3K/AKT signaling,
perhaps by IGF-I.

This study provides an insight into the role of the microenvironment, especially
low oxygen tension, in directing receptor tyrosine kinase signaling by modifying
abundance of effector kinases and signal intensity in response to growth factors,
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e.g. IGF-I. This knowledge of signaling pathways will allow for in vitro stem cell
preconditioning by growth factors, oxygen tension and chemical molecules for a
more successful use in tissue regeneration therapies mimicking that of in vivo
conditions for better engraftment and survival.

2.5.
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FIGURE S2.1. Low oxygen tension increases PMSC proliferation in
response to IGF-I. (A) P-PMSC (B) T-T-PMSC proliferation was assessed using
the Countess Cell counter. P- and T-PMSCs were treated with increasing IGF-I
concentrations (0, 10, 50,100 ng/mL) in room air or low oxygen tension for 48hrs. Two-Way ANOVA, P<0.05, n=6; a = significant difference between room air
and low oxygen tension, * = significant difference by different IGF-I
concentrations. In both P- and T-PMSCs, low oxygen tension enhanced the
effect of IGF-I on cellular proliferation.
C) Immunoblotting of p-ERK1/2 and p-AKT in Pre-term and Term PMSCs. pERK1/2 is reduced in low oxygen tension below that in room air and sensitivity to
induce p-AKT activation is reduced to higher IGF-I concentrations.
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FIGURE S2.2. IGF-IR and IRS-1 levels in response to IGF-I stimulation under
low oxygen tension is dose and time dependent. (A and B) Immunoblots of
IGF-IRα and total IRS-1 levels following treatment with different concentrations of
IGF-I (0, 10, 50, 100 ng/mL) in both P- and T-PMSCs for 48-hrs. (C and D)
Immunoblots IGF-IRα and IRS-1 levels in P-PMSCs and T-PMSCs following
treatment with IGF-I (100 ng/mL) over 48-hrs under room air and low oxygen
tension (n=3). β-Actin levels indicate equivalent protein loading. Low oxygen
tension enhance an increased level of IGF-IRα and IRS-1 in both PMSCs. IGFIRα and IRS-1 levels decrease with increased concentration of IGF-I or
stimulation time.
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FIGURE S2.3. Oxygen tension modulates the phosphorylation of IGF-IRβ
and IRS-1 (pY612 and pY896) levels in PMSCs. (A and C) P- and (B and D) TPMSCs were stimulated with an increasing concentration (0, 10, 50, 100 ng/mL)
of IGF-I or with IGF-I (100 ng/mL) over 0-48-hrs under room air or low oxygen
tension, respectively. Levels of p-IGF-IRβ, p-IRS-1pY-896and p-IRS-1pY-612 were
quantified by densitometry of immunoblots in P-PMSCs and T-PMSCs.
Quantification by densitometry was normalized to β-Actin for protein load and
DNA content to account for stem cell heterogeneity. Two-Way ANOVA, P<0.001,
n=3, a = significant difference between room air and low oxygen tension, * =
significant difference by increased IGF concentration or stimulation time.
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FIGURE S2.4. Assessment of use of MEK1/2 and PI3K inhibitor
concentrations. Immunoblots of pro-caspase-9, activated caspase-9 and PCNA
in preterm PMSCs after 48-hrs treatment. Cells were treated continually in
presence of U0126 or LY294002 for 48-hrs in presence or absence of IGF-I (100
ng/mL) to assess apoptosis (caspase-9) and proliferation (PCNA) (n=3).
Concentration of inhibitors was assessed based on highest concentration of
inhibitor that does not induce apoptosis.

92
Appendix 1

Room-air (20%O2)
1.5

1.0

*
0.5

*

*
*

0.0

0

100

p-ERK1/2 levels
compared to 0ng/mL IGF-I (-folds)

p-ERK1/2 levels
compared to 0ng/mL IGF-I (-folds)

A
Low Oxygen (1%O2)
1.5

1.0

*

0.5

*
0.0

0

*

2.0
1.5
1.0
0.5
0.0

*
0

100
IGF-I (ng/mL)

p-ERK1/2 levels
compared to 0ng/mL IGF-I (-folds)

p-ERK1/2 levels
compared to 0ng/mL IGF-I (-folds)

Room-air (20% O2)
2.5

100
IGF-I (ng/mL)

IGF-I (ng/mL)

B

DMSO
U0126
LY294002

*

Low Oxygen (1% O2)
3

DMSO
U0126
LY294002

2

*
1

*
0

0

100
IGF-I (ng/mL)

FIGURE S2.5. Effect of MEK1/2 and PI3K inhibition on p-ERK1/2 in PMSCs
under low-oxygen. (A) P-PMSCs and (B) T-PMSCs (N=2) were treated in
presence of U0126 (5 μM) or LY294002 (10 μM) in combination IGF-I (0 or 100
ng/mL) for 48-hrs under room-air or low-oxygen. Immunoblots of p-ERK1/2 were
normalized to total kinase level and β-ACTIN. DMSO is a vehicle control. (Oneway ANOVA, p<0.05, n=3, * = significant difference compared with DMSO control
at 0 ng/mL IGF-I).
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FIGURE S2.6. Effect of MEK1/2 and PI3K inhibition on p-AKT in PMSCs
under low-oxygen. (A) P-PMSCs and (B) T-PMSCs (N=2) were treated in
presence of U0126 (5 μM) or LY294002 (10 μM) in combination IGF-I (0 or 100
ng/mL) for 48-hrs under room-air or low-oxygen. Immunoblots of were
normalized to total kinase level and β-Actin. DMSO is a vehicle control. (One-way
ANOVA, p<0.05, n=3, * = significant difference compared with DMSO control at 0
ng/mL IGF-I).
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FIGURE S2.7. Effect of MEK1/2 and PI3K inhibition on OCT4 expression as
a marker for stemness in PMSCs under low-oxygen. A) P-PMSCs and (B) TPMSCs (N=2) were treated in presence of U0126 (5 μM) or LY294002 (10 μM) in
combination IGF-I (0 or 100 ng/mL) for 48-hrs under room-air or low-oxygen.
Immunoblots of were normalized to β-Actin. DMSO is a vehicle control. (One-way
ANOVA, p<0.05, n=3, * = significant difference compared with DMSO control at 0
ng/mL IGF-I).
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CHAPTER THREE
Low Oxygen Tension Modulates the Insulin-like Growth Factor Signaling
via Insulin-like Growth Factor-I Receptor and Insulin Receptor to Maintain
Stem Cell Identity in Placental Mesenchymal Stem Cells
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3.1

INTRODUCTION

Manipulating stem cells in vitro is a critical process to preserve stem cell identity
and induce fate changes towards self-renewal or differentiation (1). For tissue
regeneration therapy, it is important to prolong the characteristics of stem cell in
vitro which can be achieved by mimicking their natural microenvironment (growth
factors, extracellular matrices, oxygen tension, etc.) before their use for
successful in vivo applications (2, 3). Insulin-like growth factors (IGFs; IGF-I and
IGF-II) and oxygen tension are major stem cell niche factors in the human
placenta (4, 5). IGFs are known to manipulate stem cell fate to maintain
multipotency or induce differentiation, while continuous low oxygen tension
microenvironment inhibits stem cell differentiation and retain multipotency (6-9).

The use of IGF-I and IGF-II has become popular in cell culture systems to
maintain self-renewal or induce differentiation. IGF-I and IGF-II are polypeptide
ligands, similar to pro-insulin, that signal through the IGF-IR, a RTK, to trigger a
mitogenic response through the ERK1/2 and the AKT pathways to promote
growth and survival and inhibit apoptosis (4, 10, 11). Moreover, both IGF-I and -II
can signal through the IR or hybrid IGF-IR/IR receptor (12, 13). IGF-IR is more
sensitive to IGF-I with a Kd of 1 nM and with a 10-fold lower affinity to IGF-II (14).
In ES cells, IGF-IR is highly enriched and is required to maintain stem cell selfrenewal and pluripotency as blocking the IGF-IR reduced pluripotency and even
induced differentiation (8, 9, 15). The use of IGF-I (200 ng/mL) in defined DC-
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HAIF media (15) or IGF-II (30 ng/mL) in KOSR media (8) was sufficient to
maintain undifferentiated hESCs in vitro without the need for a feeder layer.

OCT4, NANOG and SOX2 constitute a triad of transcription factors, which
regulate human ES cell fate. They are also utilized to generate iPSCs (16-19).
Each of these transcription factors has a major role in repressing the
differentiation

process

towards

a

specific

lineage:

OCT4

represses

extraembryonic and epiblast-derived lineages, NANOG represses embryonic
ectoderm differentiation, and SOX2 represses mesendoderm differentiation (16).
In vivo, stem cells reside in a compartment with low oxygen levels (3 - 5% O2).
Therefore, low oxygen tension is an important factor modulating stem cell
identity. In hESCs, the hypoxia inducible factor 2 (HIF2), formed in low oxygen
tension, can interact with the promoter regions of OCT4, NANOG and SOX2 and
enhance their expression (20, 21). Even, when generating iPSCs, low oxygen
tension enhances reprogramming efficiency by increasing the number and size of
colonies and their expression of pluripotency genes. It is possible to form
colonies in absence of one or two of the four-transcription factors (Oct3/4, Klf4,
+/- Sox2, +/- c-Myc) only if placed in low oxygen tension (22). Therefore, it is
becoming important to culture ESCs, MSCs and iPSCs in low oxygen tension as
it may modulate cell response to intracellular/extracellular growth factors in order
to maintain stem cell character similar to in vivo conditions.
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In this context, the interaction of IGFs with their receptors (IGF-IR vs. IR) in the
stem cells is not clear and whether low oxygen tension can modify stem cell
multipotency. For this purpose, we used placental mesenchymal stem cells
(PMSCs) as a model to study the differences between IGF-I and IGF-II signaling
at low oxygen tension, a microenvironment that mimic the placenta in vivo. We
hypothesized that, under physiological low oxygen tension, IGF-I and IGF-II
regulate PMSC self-renewal capacity by utilizing different signal transduction
mechanisms via the IGF-IR. Here, we show how oxygen tension can distinctly
upregulate IGF-II expression and abundance. Also, we demonstrate that IGF
signaling via its receptor mediates PMSC signaling through ERK1/2 and AKT to
promote increased PMSC proliferation. Low oxygen tension upregulated the
expression of OCT4, NANOG and SOX2, which were lowered by IGF stimulation.
We also propose that, besides the IGF-IR, an important role of the IR becomes
prominent in enhancing PMSC proliferation under low oxygen tension conditions.

3.2.

MATERIAL AND METHODS

3.2.1. PMSC Isolation
PMSCs were isolated from early gestation human placentae - from 10-13 weeks.
For comparison between gestational ages, PMSCs were isolated from mid
gestation 20-22 week or from late gestation 37-40 weeks. After informed
consent, placentae were collected from patients who underwent therapeutic
pregnancy termination. Immediately after surgery, placentae were dissected
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under sterile conditions and small pieces of chorionic villi were collected. Tissue
samples were minced mechanically and subjected to a process consisting of two
steps of enzymatic digestion with (1) collagenase IV/hyaluronidase, and (2)
DNase I followed by (3) trypsin/EDTA. Each enzymatic step was performed for
10 min at 37ºC, followed by 10 min wash at 4ºC in a solution of PBS
supplemented with 10% fetal bovine serum (FBS) (Gibco, Mississauga, ON,
CAN). Cells released during digestion were passed through a tissue mesh (45
μm) to obtain a single cell suspension. Next, cells were separated on a Percoll
(Sigma) discontinuous gradient according to a modified protocol by Worton et al.
for hematopoietic stem cell isolation (23) and then seeded in DMEM/F12 media
(Gibco, Mississauga, ON, CAN) supplemented with 15% FBS, FGF-2 (100
ng/mL) and antibiotic-antimycotic solution (1x). After 4 days, media was changed
and non-adherent cells were washed with media to leave behind adherent
PMSCs able to form colonies.

3.2.2. Cell Culture and Incubation in Low Oxygen Tension
For each experiment, two preterm PMSC cell populations were used in triplicate.
Cells were cultured and maintained using DMEM/F12 media supplemented with
15% FBS and FGF-2 (100 ng/mL) (Gibco, Mississauga, ON, CAN). Before
treatments, cells were cultured in DMEM/F12 supplemented 10% FBS only.
Upon treatment, PMSCs were switched to fresh media containing only IGF-I or
IGF-II (0 – 100 ng/mL). For IGF-IR or IR neutralization experiments, cells were
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grown in serum-free media for 24-hrs and then specific antibodies were added at
a final concentration of 5 µg/ml in serum-free media. Then, 50 ng/ml of IGF-I or
IGF-II final concentration was added to the cell-culture for 24-hrs. Cell cultures
were then placed in either a 5% CO2 incubator or a hypoxia chamber, which was
filled with a mix of (1% O2, 5% CO2, Balanced N2) (BOC Canada Ltd, Toronto,
ON, CAN) for 15 min to ensure saturation using a Hudson 5590 Oxygen Monitor
(Hudson, Ventronics Division, Temecula, CA, USA). Thereafter, the chamber
was placed in a tissue-culture incubator at 37o C.

3.2.3. Real-time PCR
Total RNA was extracted from PMSCs using the PureLink RNA Mini Kit (Ambion,
Burlington, ON) as per the manufacturer’s protocol. Cells cultured in 60 mm
dishes were lysed in lysis buffer with 1% β-mercaptoethanol. Lysates were
scraped, collected in 1.5 mL tubes and homogenized using 21-gauge syringe
needle (10 times). Lysates were then applied to the column for binding RNA,
washed and eluted using RNase free water. 1-3 µg total RNA were reverse
transcribed into cDNA using Superscript III first-strand synthesis system for RTPCR (Invitrogen, Burlington, ON, CAN) and (25 μM) oligo (dT)20 primers in 20 µL
volume. Quantitative PCR was performed on 100 ng of cDNA using Platinum
SYBR-Green qPCR SuperMix-UDG with ROX (Invitrogen, Burlington, ON, CAN)
following the manufacturer protocol. PCR products were less than 200 bp and
each primer concentration used was 0.4µM. All reactions were run in 10µL in
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384-well plate format using the Applied Biosystems ViiA 7 System. Human
RPL13a gene was used as the reference endogenous control for normalization of
the target genes. Standard curves were generated with 5 points of cDNA (5000.05 ng/µL) besides runs without template as a negative control (NTC).
Amplifications conditions were run at 50°C for 2 min, 95°C for 10 min followed by
40 cycles of 95°C for 30 sec, 60°C for 30 sec and 72°C for 15 sec. The following
primers were used: IGF-I sense (5’- CCT CCT CGC ATC TCT TCT ACC TG-3’),
antisense (5’-CTG CTG GAG CCA TAC CCT GTG-3’); IGF-II sense (5’-CGG
CTT CTA CTT CAG CAG GC-3’), antisense (5’-TGG CGG GGG TAG CAC AGT3’); IGF-IR sense (5’-GAG CAG CTA GAA GGG AAT TAC-3’), antisense (5’-AAG
TTC TGG TTG TCG AGG A-3’); IR-A sense (5’-GTT TTC GTC CCC AGG CCA
TC-3’), antisense (5’-CCA ACA TCG CCA AGG GAC CT-3’); IR-B sense (5’-CAC
TGG TGC CGA GGA CCC TA-3’), antisense (5’- GAC CTG CGT TTC CGA GAT
GG-3’); OCT4 sense (5’-GAT GTG GTC CGA GTG TGG TTC T-3’), antisense
(5’-TGT GCA TAG TCG CTG CTT GAT-3’); SOX2 sense (5’-TTG CTG CCT CTT
TAA GAC TAG GA-3’), antisense (5’-CTG GGG CTC AAA CTT CTC TC-3’);
NANOG sense (5’-ATG CCT CAC ACG GAG ACT GT-3’), antisense (5’-AAG
TGG GTT GTT TGC CTT TG-3’)RPL13a sense (5’-CAT AGG AAG CTG GGA
GCA AG-3’), antisense (5’-GCC CTC CAA TCA GTC TTC TG-3’).
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3.2.4. Immunoblotting
Cell lysates were prepared using 1x cell lysis buffer for phospho-proteins
according to manufacturer protocol (#9803, Cell Signaling Technologies,
Burlington, ON, CAN). Protein samples (10-20 µg each) were resolved by 10%
SDS-PAGE, and then transferred onto PVDF membranes (Millipore, Bedford,
MA). The membranes were blocked with 5% bovine-serum-albumin or in 5%
non-fat-dry milk in 1x TBS (Tris-buffered saline) for 1 hr at room temperature.
Blots were then washed in 1x TBS 0.1% Tween 20 (TBS-T) (3x for 5 min)
followed by incubation at 4oC overnight with primary antibodies as per
manufacturer’s protocols. Blots then were washed using TBS-T (3x for 10 min)
and were incubated with the corresponding secondary HRP-labelled antibody for
1 hr at RT. Immunocomplexes were detected by ECL and documented using
VersaDOCTM Imaging System (Bio-Rad).

3.2.5. Antibodies
To investigate the IGF-I vs. IGF-II activated signaling proteins in PMSCs, we
used the following antibodies: phospho-p44/42 MAPK (#4377), p44/42 MAPK
(#9102) phospho-AKT (Ser473, #4051), AKT (#9272) and p-IGF-IRβ (#3918)
from (Cell Signaling Technologies, Burlington, ON, CAN) and IGF-IRα (N-20, sc712) and IGF-IRβ (C-20, sc-713) (Santa Cruz Biotech., Santa Cruz, CA, USA).
For receptor neutralization, we used IGF-IRα (1H7, sc461-L) (Santa Cruz
Biotech., Santa Cruz, CA, USA) and IRα (MA-20, NB400-142) (Novus Canada,
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Oakville, ON, CAN). For multipotency markers, we used OCT3/4 antibody (N-19,
sc-8628) (Santa Cruz Biotech., Santa Cruz, CA, USA), SOX-2 (2683-1) and
NANOG (3369-1) (Epitomics, Burlington, ON, CAN). For loading control, we used
pan-Actin Ab-5 (#MS-1295) (Thermo Fisher Scientific, Fremont, CA). The
secondary antibodies used for immunoblotting were goat anti-rabbit (#170-6515),
anti-mouse (#170-6516) HRP conjugated antibodies (BioRad laboratories,
Hercules, CA) or donkey anti-goat antibody (sc-2020) Santa Cruz Biotech., Santa
Cruz, CA, USA).

3.2.6. Statistical Analysis
All experiments were run in triplicates from three independent experiments each;
whenever possible three or more PMSC primary lines were used. All graphs and
analyses were generated using GraphPad Prism Software 5.0 (GraphPad
Software, San Diego, CA). A Two-way ANOVA with Bonferroni post hoc test was
used for the PMSC WST1 proliferation assay and densitometry quantifications.
Data are expressed as mean ± standard error of the mean (SEM); values were
considered significant when p<0.05.
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3.3.

RESULTS

3.3.1 PMSC expression of IGF-I and IGF-II is controlled by oxygen tension
and IGF stimulation
During placental development in vivo, IGFs are expressed differentially with
gestation - IGF-II is expressed earlier and in higher abundance than IGF-I (24).
This expression pattern was confirmed by PMSCs isolated from different
gestational ages only when maintained under low oxygen tension to express
higher IGF-II at early gestation and a later expression of IGF-I (Fig. S3.1). In this
study, the experiments were conducted using preterm PMSCs isolated from early
pregnancies only. They have higher levels of OCT4, the master regulator switch
of pluripotency (Fig. S3.2). IGFs are mainly secreted by the liver as endocrine
signaling factors but they are also produced in peripheral tissues as
autocrine/paracrine factors, which contribute to tissue maintenance, growth and
repair. In PMSCs, extracellular IGF-I stimulation increased IGF-I expression in
room air at 100 ng/mL (positive feedback). There were no change in expression
under low oxygen tension conditions, which demonstrated lowered basal IGF-I
expression compared to room air (Fig. 3.1A). Similarly, extracellular IGF-II
stimulation (10 and 50 ng/mL) increased IGF-I expression under room air (Fig.
3.1B). Low oxygen tension increased IGF-II expression (≥ 2-fold) that was also
increased by extracellular IGF-I (50 and 100 ng/mL) in low oxygen tension (Fig.
3.1C). With extracellular IGF-II stimulation, IGF-II expression increased in a dose
dependent response in presence of IGF-II only in low oxygen tension (Fig. 3.1D).
Therefore, expression of IGFs by PMSCs is dependent on oxygen tension - low
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FIGURE 3.1. Expression of IGF-I and -II mRNA by PMSCs is regulated by
exogenous IGF and low oxygen tension. PMSCs were cultured for 48-hrs in
either room-air or low-oxygen tension in presence or absence of IGF-I or IGF-II
(0, 10, 50, 100 ng/mL). By real-time PCR, expression level of IGF-I and -II mRNA
were measured relative to RPL13a as an endogenous control. IGF-I levels were
measured with increasing concentration of A) IGF-I or B) IGF-II. Similarly, IGF-II
mRNA levels are shown in presence of increasing concentrations of C) IGF-I or
D) IGF-II. (Two-way ANOVA, p<0.05, n=3, *= significant difference between room
air and low oxygen tension; a= significant difference of different IGF
concentrations in room air, A= significant difference of different IGF
concentrations in low oxygen tension). Low oxygen tension decreased IGF-I
expression and increased IGF-II expression in PMSCs.
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oxygen tension represses the expression of IGF-I, while it promotes the
expression of IGF-II. Both are enhanced by extracellular IGFs in an oxygen
tension-dependent manner.

3.3.2. IGF-IR and IR expression is dependent on oxygen tension and IGF
concentration
PMSCs expressed both IGF-IR and IGF-IIR, and the IR, but the IGF actions are
mediated through either the IGF-IR or IR to trigger mitogenic or metabolic
actions. We noted that IGF-IR and IR (α-subunit) levels were upregulated in
absence of IGFs and even more when combined with low oxygen tension (Fig.
3.2). In room air, the increased concentration of IGF-I or -II decreased both
receptor (IGF-IR and IR) protein levels in a dose dependent manner (more with
IGF-I than IGF-II) (Fig. 3.2 C-F), but low oxygen tension had a significant
opposing effect maintaining higher levels even in presence of IGFs (less with
IGF-I) (Fig. 3.2 C-F). The decrease in the IR levels was less than IGF-IR in
response to IGFs and the IR was increased in low oxygen tension even in
presence of IGFs. At the receptor expression level, IGF-IR receptor mRNA was
increased in low oxygen tension which was also decreased by IGF-I and -II (Fig.
S3.3A and B). PMSCs also expressed the two isoforms of IR (IR-A and IR-B)
(Fig. S3.3 C-F); however, low oxygen tension increased IR-A expression several
fold compared with the IR-B.
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FIGURE 3.2. IGF-IR and IR levels are decreased by IGF-I and -II but elevated
by low oxygen tension. PMSCs were cultured for 48-hrs in either room air or
low oxygen tension in presence or absence of IGF-I or IGF-II (0, 10, 50, 100
ng/mL). By Immunoblotting, protein expression levels of IGF-IRα or IRα was
detected in presence of increasing concentration of A) IGF-I or B) IGF-II. The βsubunits of both receptors showed similar protein levels with the different
treatments. C-F) blot quantifications for both receptors are shown. β-Actin is used
as a protein loading control. (Two-way ANOVA, p<0.05, n=3, *= significant
difference between room air and low oxygen tension; a= significant difference of
different IGF concentrations in room air, A= significant difference of different IGF
concentrations in low oxygen tension). Low oxygen tension maintained higher
levels of both receptors that were otherwise decreased with increasing
concentration of IGFs in room air.
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In the presence of IGF-II (100 ng/mL), IR-A level was decreased in low oxygen
tension; this was similar to IR-B abundance (Fig. S3.3D and F). Therefore, the
expression profile and protein levels of the IR was similar to IGF-IR response in
the presence of IGFs, indicating that similar signaling mechanism controls IGF-IR
and IR in PMSCs from early gestation placentae. Also, low oxygen tension
opposed the negative regulation of IGF-IR or the IR by IGFs; the increased IGFIR or IR expression would allow increased responsiveness to IGFs.

3.3.3. Activation of IGF-IR signaling pathway in PMSCs is regulated by
oxygen tension
IGF-I and IGF-II bind and activate the IGF-IR, but due to binding affinity, IGF-IR
phosphorylation and activation varies especially in short term stimulation. In room
air, the phosphorylation of the IGF-IR (β-subunit) was more sensitive to IGF-I
than IGF-II (Fig. 3.3), whereas in low oxygen tension the sensitivity to IGF-I or
IGF-II was decreased (Fig. 3.3A and B).
The propagation of IGF-IR activation following short-term stimulation was tested
via the phosphorylation of major signaling kinases downstream, ERK1/2 and
AKT. In room air, ERK1/2 phosphorylation was similar with either IGF-I or -II (Fig.
3.4A and B). However, low oxygen tension caused an increase in p-ERK1/2
levels in response to IGF-I greater than that induced in room air (Fig. 3.4A). The
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FIGURE 3.3. IGF-IR phosphorylation is dependent on IGF ligand,
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either room air or low oxygen tension in presence or absence of A) IGF-I or B)
IGF-II (0, 10, 50, 100 ng/mL) following serum deprivation for 24-hrs. From
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110
B

A

15 min

C

C

a,b

b

B
2.5
a
0.0

a,b

A
0

C

10
50
IGF-I (ng/mL)

100

1.5

*
a

1.0

*
a
b

0.5
A
0.0

0

A

5.0

Room-air
Low-oxygen

2.5
a
0.0

A
0

D

48 hrs

p-ERK1/2 levels (-fold)

p-ERK1/2 levels (-fold)

5.0

A

10
50
IGF-I (ng/mL)

A
b
100

a

a,b

b
A

A

A

10
50
IGF-II (ng/mL)

100

48 hrs

p-ERK1/2 levels (-fold)

p-ERK1/2 levels (-fold)

15 min

1.5

*
a

1.0

ab
b

0.5
A
0.0

0

A

A

10
50
IGF-II (ng/mL)

A
b
100

111
F

E

15 min

200
c

150
100
50
0

A

B

b

p-AKT levels (-fold)

p-AKT levels (-fold)

15 min

c

B

a
0

10
50
IGF-I (ng/mL)

200
150
100
50
0

100

G

c

b
A
a

A
a
0

A

A

10
50
IGF-II (ng/mL)

100

H
48 hrs
*

2.5
2.0

b

1.5
1.0

a

0.5

A

0.0

0

a

b

B
AB

A
10
50
IGF-I (ng/mL)

100

p-AKT levels (-fold)

p-AKT levels (-fold)

48 hrs
2.5
2.0

b

1.5
1.0
0.5
0.0

a
A
0

a
A

A

B

a

10
50
IGF-II (ng/mL)

100

FIGURE 3.4. ERK1/2 and AKT phosphorylation in PMSCs is dependent on
IGF concentration and oxygen tension. PMSCs were stimulated for 15 min or
48-hrs in either room air or low oxygen tension in presence or absence of IGF-I
or IGF-II (0, 10, 50, 100 ng/mL). From Immunoblotting, detected levels of (A – D)
p-ERK1/2 and (E – H) p-AKT were quantified and normalized to total kinase level
and to β-actin, used as a protein loading control. (Two-way ANOVA, p<0.05, n=3,
*= significant difference between room air and low oxygen tension; a= significant
difference of different IGF concentrations in room air, A= significant difference of
different IGF concentrations in low oxygen tension). In short term, Low oxygen
tension potentiates p-ERK1/2 signal and represses p-AKT. In long term, Low
oxygen tension, maintains lower p-ERK1/2 than room air and elevated p-AKT
levels similar to room air.
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IGF-II effect was not seen in low oxygen tension (Fig. 3.4B). AKT
phosphorylation was more sensitive to IGF-I, similar to IGF-IRβ phosphorylation.
In room air, AKT phosphorylation plateaued at 50 ng/mL of IGF-I while IGF-II
induced the highest activation at 100 ng/mL (Fig. 3.3E and F). On the other hand,
low oxygen tension lowered the phosphorylation levels of AKT in a similar pattern
to p-IGF-IRβ (Fig. 3.4E and F). Overall, low oxygen tension reduced the
phosphorylation of IGF-IRβ and AKT in a similar manner, and increased the
phosphorylation of ERK1/2 in presence of IGF-I.
Long-term phosphorylation of ERK1/2 and AKT can be indicators of stem cell
state of proliferation. Continuous stimulation of PMSCs by IGF-I and -II in room
air, caused a dose-dependent decrease in p-ERK1/2 levels similar to low oxygen
tension (Fig. 3.4C and D). Phospho-AKT had an opposite activation pattern
compared with p-EKR1/2 that caused a dose dependent increase with IGF-I or -II
in both oxygen tensions (IGF-I being more potent than IGF-II) (Fig. 3.4G and H).
Therefore, low oxygen can maintain a narrow range of p-ERK1/2 levels but does
not interfere with p-AKT pathway that is dependent on IGF stimulation.

3.3.4. Expression of stem cell-associated genes in PMSCs is regulated by
low oxygen tension and IGFs
Stem cell fate is determined by their microenvironment, and the expression of the
pluripotency genes, OCT4, NANOG and SOX2, determines the character of
stemness in hESCs and iPSCs. In PMSCs, all three genes are expressed and
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regulated by low oxygen tension and IGFs. Low oxygen tension increased OCT4,
NANOG and SOX2 mRNA levels and was decreased by IGFs (Fig. S3.4).
However, IGFs maintained a higher expression of the three genes in low oxygen
tension condition only (IGF-II more prominent than IGF-I to enhance expression
72-hrs post stimulation) (Fig. S3.5). Transcription factors function at the protein
level as they physically interact with DNA to regulate multipotency gene
expression and fate changes. OCT4 protein levels did not change with increasing
concentrations of IGF-I or IGF-II in either room air or low oxygen tension (Fig.
3.5A). However, SOX2 and NANOG expression was affected by IGF-I or IGF-II
at both mRNA and protein. Levels of NANOG and SOX2 were increased at 10
ng/mL IGF-I and IGF-II then decreased in presence of increased concentrations
of IGF-I or IGF-II (Fig. 3.5B and C). Therefore, OCT4 was unchanged by IGF and
oxygen tension, although it was reduced at the mRNA level at increasing IGF-I.
NANOG and SOX2 were elevated by low oxygen tension and decreased by IGF-I
but not IGF-II stimulation. This shows that low oxygen tension can maintain or
enhance multipotency but IGF-I and less with IGF-II (depending on concentration
and stimulation time) oppose this effect.
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FIGURE 3.5. NANOG and SOX2 but not OCT4 are decreased by IGFs and
increased by low oxygen tension in PMSCs. PMSCs were stimulated for 48hrs in either room air or low oxygen tension in presence or absence of IGF-I or
IGF-II (0, 10, 50, 100 ng/mL). From Immunoblotting, detected levels of A) OCT4,
B) NANOG and C) SOX2 were quantified and normalized to β-actin, used as a
protein loading control. (Two-way ANOVA, p<0.05, n=3, *= significant difference
between room air and low oxygen tension; a= significant difference of different
IGF concentrations in room air, A= significant difference of different IGF
concentrations in low oxygen tension). Low oxygen tension was able to elevate
the levels of NANOG or SOX2 but not OCT4, whereas increased IGF
concentration caused a decrease in total levels.
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3.3.5. PMSC proliferation is enhanced by IGFs in low oxygen tension
Self-renewal is an important stem cell characteristic. We assessed PMSC
proliferation as an indicator of self-renewal by oxygen tension and IGF-I or IGF-II
concentration. In room air, IGF-I stimulated proliferation in a dose dependent
manner that plateaued at (50 ng/mL), but was increased further if maintained in
low oxygen tension (Fig. 3.6A). Interestingly, proliferation decreased when
concentrations greater than 100 ng/mL of IGF-I was added in room air, but not in
low oxygen tension (data not shown). In comparison, the effect of IGF-II was
lower than that of IGF-I on PMSC proliferation in room air and was enhanced by
low oxygen tension (Fig. 3.6B). Therefore, IGF-I is more potent in stimulating
PMSC proliferation in room air, whereas, low oxygen tension potentiates both
IGF-I and -II signaling to stimulate increased proliferation. These results show
that a lowered p-ERK1/2 and increased p-AKT levels (Fig. 3.4) correlates with an
IGF-stimulated proliferation.

3.3.6. Low oxygen tension mediates a differential IGF signaling through the
IGF-IR and IR to stimulate proliferation
Low oxygen tension upregulated IGF-IR and IR expression. In room air,
neutralizing the IGF-IR abolished the effect of IGF-I or -II stimulation; however, in
low oxygen tension, the IGF-mediated proliferation remained elevated even in
the presence of a 10-fold excess of antibody (Fig. S3.6). This finding suggests
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presence of increasing concentration of A) IGF-I or B) IGF-II (0, 10, 50, 100
ng/mL) under room air or low oxygen tension for 48-hrs. Neutralization effect of
IGF-IR or IR was measured in presence of 5 µg/mL of either neutralizing
antibody in presence of 50 ng/mL of C) IGF-I or D) IGF-II in room air or low
oxygen tension conditions for 24-hrs. The absorbance was read at 450 nm with a
background reference of 650 nm. (Two-Way ANOVA, P<0.05, n=8, * = significant
difference between room air and low oxygen tension, + = significant difference by
IGF concentration in comparison with 0 ng/mL IGF). Low oxygen tension
enhanced PMSC proliferation and increased the IGF effect in increasing PMSC
proliferation. IGF-IR and IR are responsible for mediating IGF signaling to
increase PMSC proliferation especially under low oxygen tension conditions. IGF
enhanced proliferation in absence of exogenous IGF is mediated by endogenous
IGF expression.
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that the effect of IGF-I or -II was mediated additionally by another receptor. We
tested whether IR was this receptor. In room air, IGF-I or IGF-II mediated
proliferation was reduced by the IGF-IR neutralizing antibody and by IR
neutralizing antibody (Fig. 3.6C and D). The reduction in proliferation was lower
than without IGFs, suggesting that a portion of the proliferative response was due
to endogenous IGF. On the other hand, low oxygen tension enhanced PMSC
proliferation, and neutralizing the IGF-IR had a greater effect than IR
neutralization (Fig. 3.6C). A combination of both receptor neutralizing antibodies
completely abolished the IGF-I induced proliferation, suggesting a potential role
for the hybrid receptor under this condition. Similarly in low oxygen tension, IGFII stimulation was more reduced by neutralizing the IR (Fig. 3.6D). The PMSC IRmediated proliferation was dependent on IGF stimulation as insulin stimulation
alone did not increase proliferation regardless of oxygen tension (Fig. S3.7).
Therefore, IGFs utilized both the IGF-IR and IR to promote PMSC proliferation,
however, low oxygen tension can modulate IGF signaling response towards IGFIR for IGF-I signaling and the IR for IGF-II signaling. As mediators of IGF-IR/IR
signaling, we checked the ERK1/2 and AKT phosphorylation levels. The
presence of either IGF-IR or IR neutralizing antibody negated the effect of IGF-I
by decreasing ERK1/2 phosphorylation (Fig. 3.7A). No major changes in pERK1/2 levels were detected with IGF-II (Fig. 3.7B). AKT was more responsive
to IGF stimulation, which was inhibited by IGF-IR and IR neutralizing antibodies.

118

B

II

II

/IG
F-

F-

1H
†

#

# #

1

IR

F-

/IG
F-

II

II

0

7/
IG

IR

/IG

FI

FI

1H
7/
IG

IG

F-

I

0

†

2

1H

1

3

II

2

IR

IG
#

F-

#

3

4

IG

†

5

0

4

7/
IG

0

/IG
IR

1H
5

0

D

†

0

p-AKT levels (-fold)

C

1

FI

FI
7/
IG

IG

FI

0

ns.

FII

p-ERK1/2 levels (-fold)

† †

p-AKT levels (-fold)

1

0

p-ERK1/2 levels (-fold)

A

FIGURE 3.7. IGF-mediated p-ERK1/2 and p-AKT signaling in PMSCs under
low oxygen tension is partially regulated through the IGF-IR giving the IR a
role in low oxygen tension. PMSC were stimulated in presence of 5 µg/mL of
IG-IR or IR neutralizing antibodies in presence of A) and C) IGF-I (50 ng/mL) or
B) and D) IGF-II (50 ng/mL) under room air or low oxygen for 24-hrs. From
Immunoblots, detected levels of A) and B) p-ERK1/2 and C) and D) p-AKT were
quantified and normalized to total kinase level followed by normalization to βactin used as a protein loading control. (Two-way ANOVA, p<0.05, n=3, † =
significant difference by IGF concentration compared with 0 ng/mL, # =
significant difference by the neutralization antibody effect compared with IGF
alone). ERK1/2 phosphorylation was not decreased by antibody neutralization of
IGF-IR or IR in PMSCs in presence of IGF-I. p-AKT was dependent on IGF-IR in
room air but more dependent on the IR in low oxygen tension conditions.
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As demonstrated earlier, increased p-AKT by IGF-I or -II is required for
proliferation. IGF-IR neutralization in room air mediated a decrease only in the
IGF-I induced p-AKT, whereas the IGF-II induced p-AKT was decreased in both
oxygen tensions. IR neutralization had a more significant effect in low oxygen
tension regardless of IGF-I or -II (Fig. 3.7 C and D). These results confirm that
phosphorylation of AKT is more dependent on IGF signaling, than ERK1/2, in
PMSCs and that low oxygen tension can differently mediate the IGF signaling
through either the IGF-IR or the IR indicating an important role of the IR in low
oxygen tension to mediate higher p-AKT levels and higher proliferation.

3.4.

DISCUSSION

In this study, we have demonstrated that low oxygen tension can modulate
PMSC response to IGF mediated signaling, proliferation and multipotency. We
showed that low oxygen tension and not room air promoted the increased
expression of IGF-II and less of IGF-I, and enhanced IGF-IR and IR expression.
Moreover, low oxygen tension repressed the short-term stimulation of p-IGF-IRβ
and p-AKT, while it potentiated p-ERK1/2 in the presence of IGF-I. However,
after a prolonged stimulation with IGFs, low oxygen tension maintained a low
level of p-ERK1/2 and mediated a dose dependent increase in p-AKT levels.
Among the pluripotency transcription factors, we found that OCT4 is more stably
maintained and is less altered by IGFs and oxygen tension, unlike NANOG and
SOX2. PMSC proliferation was enhanced in low oxygen tension that potentiated
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the effects of IGF-I and -II for higher proliferation level via the cooperative action
of IGF-IR and IR.

In the human placental mesodermal core, where placental mesenchymal stem
cells (PMSCs) reside, IGF-II is more abundantly expressed as early as 6-weeks
of gestation (first trimester) compared with IGF-I which begins after 12-weeks of
gestation (second trimester onwards) (24). This suggests that IGF-II plays a
major role in early placental development, possibly facilitating cytotrophoblast
invasion and angiogenesis just preceding the formation of uterine circulation (25,
26). Oxygen tension is an important microenvironmental factor in influencing
growth factor expression and signaling. In particular, low oxygen tension can
induce IGF-II gene expression in primary rat osteoblasts or human hepatoma
cells in culture (27, 28). As previously shown, IGF-II is important to maintain
embryonic stem cell identity as it is expressed by the surrounding differentiated
fibroblast cells (8). In this study, we demonstrated a relationship between oxygen
tension and the type of IGF ligand expressed by PMSCs (IGF-II in low oxygen
and IGF-I in room air). Although, in early gestation placentae, low oxygen tension
is known to have an abundant expression of IGF-II in vivo (24), PMSCs from
different gestational stages still expressed high IGF-II when maintained under
low oxygen tension conditions. Therefore, the increased expression of IGF-II can
be solely due to low oxygen tension. Hence, maintaining PMSCs in a
microenvironment that mimics their natural conditions can program PMSCs to
adapt and behave as in vivo.
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Among the pluripotency triad of transcription factors, OCT4 is regarded as the
master regulator and gatekeeper of pluripotency to keep stem cells in
undifferentiated state and prevent differentiation of hESCs into trophoblast-like
cells (29-32). OCT4 is an indispensible transcription factor to induce pluripotency
in iPSCs (18, 19, 32, 33). Also, OCT4 alone was sufficient to generate iPSCs, if
neural progenitor cells, which already express endogenous SOX2, c-MYC and
KLF4, were used for reprogramming (34). In our PMSCs, OCT4 protein levels
were less susceptible to change, unlike NANOG and SOX2, in the presence of
IGF-I or -II regardless of oxygen tension. This could be due to OCT4 being
central for pluripotency and as a master regulator to keep stem cells in
undifferentiated state, as it is tightly regulated (within 0.5-fold) to prevent
differentiation or de-differentiation of hESCs (29, 30). In support of IGF and low
oxygen tension maintenance of multipotency, we showed that low IGF
concentrations could maintain higher levels of NANOG and SOX2.

Activation of ERK1/2 and AKT signaling pathways is important in the
maintenance of stem cell proliferation and multipotency. Interestingly, the role of
ERK1/2 and/or AKT was dependent on oxygen tension. In differentiation studies,
increased activation of ERK1/2 in low oxygen tension conditions promoted
proliferation while AKT activation in room air promoted differentiation of
myoblasts in culture (35). Inhibition studies done by others and us demonstrate
that AKT activation is more important to maintain stem cell potency as measured
by OCT4, NANOG and SOX2 levels (36). Also, the induction of PI3K/AKT
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signaling pathway has been demonstrated to be central for pluripotency
maintenance of hESCs by participating in promoting proliferation, preventing
apoptosis and enhancing telomerase activity (37). The direct regulation of stem
cell pluripotency by IGF signaling is not clear; however, it is proposed that IGF
signaling can maintain pluripotency by phosphorylating the tumour suppressor
p53, which acts as a negative regulator at OCT4 and NANOG promoters, and
therefore IGF actions would disallow senescence and pluripotency gene
repression (37). Apart from direct phosphorylation of p53, AKT can antagonize
p53 by the direct phosphorylation of Mdm2 that in turn facilitates p53
ubiquitination and degradation (38), hence decrease multipotency gene
repression in stem cells. Therefore, a similar mechanism carried on by p-AKT
can play a role in enhancing PMSC multipotency at the gene regulation level.

In PMSCs, low oxygen tension modified IGF signaling starting at initial
stimulation and also at prolonged stimulation. Low oxygen decreased the
phosphorylation/activation of IGF-IRβ, ERK1/2 and AKT although an increased
expression of the IGF-IR was evident. These changes can be due to changes in
the phosphorylation mechanism or IGF binding sensitivity to IGF-IR and
combination with IR, which is still unclear in low oxygen tension. However,
ERK1/2 phosphorylation by IGF-I was transiently higher in low oxygen tension
than in room air. It was shown that transient high p-ERK1/2 levels promote
proliferation (39). A prolonged stimulation (48-hrs) with increasing concentration
of IGF-I and -II changed the levels of ERK1/2 and AKT phosphorylation in
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opposite directions, where the latter increased in a dose-dependent manner. In
low oxygen tension, ERK1/2 was lowered even with IGF stimulation, possibly to
maintain higher PMSC proliferation and inhibit differentiation. Therefore, low
oxygen tension maybe required to decrease the continuous p-ERK1/2 level, as it
is demonstrated that prolonged p-ERK1/2 levels are required for differentiation
(39). In PMSCs, ERK1/2 is less dependent on IGF stimulation than AKT as
shown by receptor activation. This was also shown from the receptor
neutralization that IGF signaling is more critical for AKT than ERK1/2
phosphorylation, which demonstrated the dependence of AKT on IGF
stimulation, especially in presence of IGF-I, to mediate stem cell proliferation.

Signaling through the IGF-IR is important to maintain stem cells in self-renewal
state (8, 9). PMSC proliferation was dependent on the IGF-IR stimulation in room
air and partially when in low oxygen tension. Both the IGF-IR and IR, which were
upregulated in low oxygen tension, participated in mediating the IGF actions to
induce PMSC proliferation in low oxygen tension. Interestingly, in neural
progenitor stem cells, proliferation was dependent on IGF-II, which was mediated
via the IGF-IR, while the IR-A had a more important role in maintaining selfrenewal than IGF-IR (40). Therefore, as PMSCs express both higher IGF-II and
IR-A in low oxygen tension, it is possible that there is dependence on IGF-II/IR-A
signaling to maintain PMSC multipotency and proliferation. IGF-II plays a major
role in placental development, as the IGF-II knockout mice, but not the IGF-I or
IGFIR knockout mice, caused a more significant growth reduction in mouse
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placenta (10, 41). Therefore, our data suggests that human stem cells may also
carry this dependence on IGF-II/IR when maintained in low oxygen tension
conditions. Also, IGF signaling utilizes the IR in addition to IGF-IR, to maintain
AKT phosphorylation, possibly due to the higher expression of the IR in low
oxygen tension. We propose that the IR homodimer or the hybrid with the IGF-IR
increases in low oxygen tension due to increased expression, and therefore can
maintain stem cell character to in response of IGF-II signaling.

Overall, placental stem cells are sensitive to their microenvironment with a higher
dependence on low oxygen tension. We showed that culturing PMSCs under low
oxygen tension modifies IGF signaling through the IGF-IR via ERK1/2 and AKT,
suggesting that those two kinases participate in the regulation of stem cell fate.
Also, we show that low oxygen tension can modify the stem cell dependence on
IGF-IR by utilizing other signaling pathways, such as the IR, to maintain PMSC
proliferation and multipotency. Thus, maintaining stem cells under low oxygen
tension, similar to in vivo conditions, may be important in maintaining stem cell
natural behaviour in preparation for regenerative therapy.

3.5
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FIGURE S3.1. IGF ligand type expression in PMSCs is gestational age and
oxygen tension dependent. PMSCs isolated from 11, 22, 38 weeks placentae
were cultured for 48-hrs in either room-air or low-oxygen tension in serum and
growth factor free conditions. By real-time PCR, expression level of IGF-I and -II
mRNA were measured relative to RPL13a as an endogenous control. IGF-I
levels were measured with increasing concentration of A) IGF-I or B) IGF-II.
(Two-way ANOVA, p<0.05, n=3). IGF-I expression is elevated in room air at later
gestation that is reduced further with PMSCs are maintained in low oxygen
tension. IGF-II expression is higher at earlier gestation PMSCs and is enhanced
by low oxygen.
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FIGURE S3.2. PMSC stemness as measured by OCT4 is gestational age and
oxygen tension dependent. PMSCs isolated from 11, 22, 38 weeks placentae
were cultured for 48-hrs in either room-air or low-oxygen tension in 10% fetal
bovine serum conditions. By immunoblotting, level of OCT4 protein levels were
measured and normalized against β-Actin as an endogenous control. (Two-way
ANOVA, p<0.05, n=3, * = significant difference between low oxygen tension and
room air, # = significant difference by comparing gestational age). OCT4 from
different gestations is maintained at higher levels by low oxygen tension.

131

A

B

IGF-IR mRNA levels (-fold)

IGF-IR mRNA levels (-fold)

Appendix 2

2.5 *
*
*
*
C
2.0
B
1.5 a A
D
b
b
b
1.0
0.5
0.0
0
10
50 100
IGF-I (ng/mL)

C

Low-oxygen

2.5 *
*
*
C
2.0
B
A
1.5 a
a
b D
b
1.0
0.5
0.0
0
10
50 100
IGF-II (ng/mL)

60

*

*

*

#

*

#

40
20
0

0

10
50
IGF-I (ng/mL)

#

*

20
0

0

60
*

*

40

*

#

20
0

Room-air
Low-oxygen
*

0

10
50
IGF-II (ng/mL)

100

F 60

*
*

40

100

IR-A mRNA levels (-fold)

60

10
50
IGF-I (ng/mL)

100

IR-B mRNA levels (-fold)

IR-A mRNA levels (-fold)

D

IR-B mRNA levels (-fold)

E

Room-air

40

*

*

*
#

20
0

0

10
50
IGF-II (ng/mL)

100

FIGURE S3.3. IGF-IR and IR mRNA expression are decreased by IGF-I and II but elevated by low oxygen tension. PMSCs were cultured for 48-hrs in
either room air or low oxygen tension in presence or absence of IGF-I or IGF-II
(0, 10, 50, 100 ng/mL). By real-time PCR, expression level of A) and B) IGF-IR
or C) and D) IR-A or E) and F) IR-B mRNA were measured relative to RPL13a as
an endogenous control in presence of IGF-I or IGF-II. (Two-way ANOVA, p<0.05,
n=3, * = significant difference between room air and low oxygen tension, # =
significant difference by different IGF concentrations).

132
Appendix 2

*

A

4

*

B
C

C

2 a
0

*

ab

0

b

b

10
50
IGF-I (ng/mL)

100

6

*

4

A

2
0

*

a

B
bc

0

a

2 a

0

*
A

A

4

0

*

C

C
cd

d
100

6

*

*
A

4
2 a
0

a

0

*

B
a

10
50
IGF-II (ng/mL)

B
a

#

100

6

*

a

2 a

0

B
ab

C
b

10
50
IGF-I (ng/mL)

100

SOX2

*
B

A

4

0

*

Room-air
Low-oxygen
*

*
A

NANOG
mRNA expression (-fold)

mRNA expression (-fold)

*

*

10
50
IGF-I (ng/mL)

OCT4
6

*

mRNA expression (-fold)

*

*
A

b

10
50
IGF-II (ng/mL)

A
A

100

mRNA expression (-fold)

6

SOX2

NANOG
mRNA expression (-fold)

mRNA expression (-fold)

OCT4

6

*
A

4

0

*

*

B

AC
a

2 a
0

*
AB

a

10
50
IGF-II (ng/mL)

a

100

FIGURE S3.4. OCT4, NANOG and SOX2 expression is affected by IGF-I or II concentration depending on oxygen tension. PMSCs were cultured for 48hrs in either room air or low oxygen tension in presence or absence of IGF-I or
IGF-II (0, 10, 50, 100 ng/mL). By real-time PCR, expression level of OCT4 or
NANOG or SOX2 mRNA was measured relative to RPL13a as an endogenous
control in presence of IGF-I or IGF-II. (Two-way ANOVA, p<0.05, n=3, *=
significant difference between room air and low oxygen tension; a= significant
difference of different IGF concentrations in room air, A= significant difference of
different IGF concentrations in low oxygen tension). Low oxygen tension
increased pluripotency associated gene expression where IGF treatment reduces
them (more with IGF-I than IGF-II).

133
Appendix 2
Room-air
Low-oxygen

5
4
3
2
1

*

*

B

B
a

0

b

A
a

24

48
Time (-hrs)

72

OCT4 mRNA expression (-fold)

IGF-Free (0 ng/mL)

OCT4 mRNA expression (-fold)

OCT4 mRNA expression (-fold)

A
IGF-I (100 ng/mL)
5
4

*

*

3

A

a

2

A

1
0

B

a

a

24

48
Time (-hrs)

72

IGF-II (100 ng/mL)

*

5

B

4

*

A

3
2

a

A

a

a

1
0

24

48
Time (-hrs)

72

IGF-Free (0 ng/mL)
5
4

*

*

3
2
1

A

a

0

24

B

A

a

a

48
Time (-hrs)

72

NANOG mRNA expression (-fold)

NANOG mRNA expression (-fold)

NANOG mRNA expression (-fold)

B
IGF-I (100 ng/mL)
5
4

*

3
2

*
A

a
A

1
0

B

a

24

a

48
Time (-hrs)

72

IGF-II (100 ng/mL)

*

5

C

4

*

B

3
2

b

a

a

a

1
0

24

48
Time (-hrs)

72

5
4

*

3

A

2
1
0

a

A

A
a

24

48
Time (-hrs)

a

72

IGF-I (100 ng/mL)
5
4

*

*

3
2
1
0

B
a

A

A
a

24

48
Time (-hrs)

b

72

SOX2 mRNA expression (-fold)

IGF-Free (0 ng/mL)

SOX2 mRNA expression (-fold)

SOX2 mRNA expression (-fold)

C
IGF-II (100 ng/mL) *
B

7
5
4
3
2
1
0

A

a

24

a

A

48
Time (-hrs)

a

72

FIGURE S3.5. OCT4, NANOG and SOX2 expression is increased by IGF-I or
-II oxygen tension. PMSCs (N=2) were cultured for 24, 48 or 72-hrs in either
room air or low oxygen tension in presence or absence of IGF-I or IGF-II (100
ng/mL). By real-time PCR, expression level of A) OCT4 or B) NANOG or C)
SOX2 mRNA was measured relative to RPL13a as an endogenous control in
presence of IGF-I or IGF-II. (Two-way ANOVA, p<0.05, n=3, *= significant
difference between room air and low oxygen tension; a= significant difference of
different IGF concentrations in room air, A= significant difference of different IGF
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FIGURE S3.7. PMSC proliferation is not responsive to insulin stimulation
even in low oxygen tension. PMSC proliferation was assessed using the WST1 colorimetric proliferation assay in presence of increasing concentration of
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and low oxygen tension). Low oxygen tension enhanced PMSC proliferation
without an effect of increasing concentration of insulin.
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CHAPTER FOUR
Insulin-like Growth Factor and Low Oxygen Tension Regulate Osteogenic
Differentiation of Placental Mesenchymal Stem Cell
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4.1.

INTRODUCTION

Mesenchymal stem cells (MSCs) are found in many adult tissues and are
responsible for tissue repair and homeostasis (1). Unlike ESCs, MSCs are less
tumorigenic and have a more restricted mesendodermal lineage-specific
differentiation (2) towards myocytes, osteoblasts, chondrocytes, adipocytes,
stromal fibroblasts, and endothelial cells (1, 3, 4). In addition, MSCs have been
demonstrated to form neuroblasts in vitro, and neuron-like cells bearing axons
and dendrites in vivo (5). Also, MSCs can modulate the immune response and
were successfully used in graft vs. host disease resistant patients (6). Therefore,
MSCs are increasing in promise for stem cell-based therapies to treat many adult
and paediatric diseases, such as sickle cell disease (7), rheumatic diseases (8),
lymphoma (9), and heart failure (10).

In bone, MSC transplantation has been utilized to correct bone malformation and
injury. Osteogenesis imperfecta (OI) is a severe pediatric genetic disorder of
mesenchymal cells with a deficit for type-I collagen synthesis, which is critical for
matrix deposition and mineralization in bone (11). There is no treatment for OI,
however, an allogeneic bone-marrow transplantation was shown to successfully
accelerate linear growth and increase total body bone mineral density in children
with OI (11). Also in bone injury, MSCs have the potential to treat the more
severe nonunion bone fractures and accelerate recovery of delayed union. In a
mouse

model,

bone-marrow

MSCs

administered

by

systemic

infusion
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successfully homed to the fracture site and accelerated the initiation of a callus
and improved the cartilage and bone content (12). Therefore, the use of MSCs
for the treatment of bone diseases and injury is a promising regenerative therapy.

Although bone-marrow MSCs have been used for stem cell therapy (13, 14), the
challenge has been their availability. Placental MSCs (PMSCs) are abundant,
readily available and do not require invasive isolation techniques (15). PMSCs
are isolated from different parts of the placenta (amnion, chorion and umbilical
cord) and have a higher proliferation capacity than bone-marrow MSCs (15). In
culture, MSCs are dependent on their surrounding microenvironment for
maintaining stem cell identity, and they differentiate by the signaling by several
growth promoting factors and the use of lineage specific cell culture conditions
(16, 17). In this microenvironment, several clues regulate stem cell differentiation
by a tight transcriptional network of losing multipotency and initiating linagespecific differentiation. In osteoblast differentiation, RUNX2 is known as a
lineage-specific regulator transcription factor that upregulates transcription of
genes required for bone matrix deposition and mineralization including
osteopontin (OPN), osteocalcin, type-I collagen, alkaline phosphatase, etc. (1821). In this process, RUNX2 is strongly detected in preosteoblasts, immature
osteoblasts, and early osteoblasts. However, its continued expression at later
stages of mature osteoblast differentiation inhibits complete differentiation (20,
22).
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In the stem cell microenvironment, MSCs reside in low oxygen tension, which
promotes stem cell proliferation, self-renewal and multipotency (23). However,
low oxygen tension can severely inhibit osteoblast differentiation in vitro (24),
while re-exposure to room air restores differentiation and may potentiate
osteogenic differentiation (25, 26). In this process, the hypoxia inducible factor
(HIF) system is responsible for downregulating the expression of osteoblast
commitment genes, such as RUNX2 (27, 28), and a complete differentiation is
obscured due to inhibition of expression of downstream genes responsible for
mineralization and matrix formation (27). However, in vivo, inhibiting cellular
responses in low oxygen tension by HIF1α knockout decreases trabecular bone
volume, reduces bone formation rate, alters cortical bone architecture and
reduces proliferation of osteoblasts during long bone development (29). In
contrast, an over-expression of HIF-1α in osteoblasts leads to the development
of extremely dense and heavily vascularized long bones (30). Therefore, the
regulation of gene expression by low oxygen tension is required for healthy
development of bone in vivo at least at the initial stages as confirmed by
preconditioning experiments. In this context, long-term exposure to low oxygen
tension is inhibitory to stem cell differentiation, although a short term exposure
can play a role in directing stem cell fate towards osteogenic differentiation (25).

In addition to oxygen tension, stem cell differentiation conditions can be defined
by soluble factors, small molecules, hormones, and growth factors. The insulinlike growth factors (IGFs, IGF-I and IGF-II) can promote and stimulate stem cell
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differentiation towards hepatic (31), endothelial (32), adipogenic (33) and
osteogenic (34, 35) lineages. In osteogenic tissues, the expression of IGF-I, IGFII and their receptor IGF-IR, has a strong association with osteogenesis and are
abundantly expressed specifically in mature osteoblasts and osteoclasts by
autocrine/endocrine mechanisms (36). The IGF-I and IGF-IR null mice show
short bone, low bone mineral density, and delayed calcification, whereas, IGF-II
null mice show no major skeletal defects (37). IGFs have no effect on osteoblast
differentiation commitment (no change in RUNX2 expression), but enhance the
differentiation function by promoting growth, inhibiting apoptosis and upregulating
matrix maturation (increased type-I collagen) and mineralization (38). Also, in
vivo, the use of MSCs that overexpress IGF-I improves fracture healing by
accelerating bone cell differentiation which is dependent on IRS1-PI3K pathway
in mediating the IGF-I dependent osteogenic actions via paracrine and autocrine
functions (39).

IGFs and low oxygen tension are endogenous components of the osteogenic
microenvironment, which are shown to affect later stages of osteogenic
differentiation during the mineralization period of MSC differentiation (27, 38).
However, the combined effect of these two microenvironmental factors on the
commitment and early differentiation stages has not been investigated. In this
study, we used MSCs isolated from the chorionic villi of the human placenta
(PMSCs) to study the role of IGF-I and IGF-II signaling in combination of low
oxygen tension in osteogenic differentiation. We show that low oxygen tension
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inhibits the differentiation of PMSCs towards the osteogenic lineage and IGF-I
enhances differentiation via specific signaling pathways.

4.2. MATERIAL AND METHODS
4.2.1. PMSC Isolation
PMSCs were isolated from early gestation (10-13 weeks) human placentae. After
informed consent, preterm placentae were collected from patients who
underwent therapeutic pregnancy termination. Immediately after surgery,
placentae were dissected under sterile conditions and small pieces of chorionic
villi were collected. Tissue samples were minced mechanically and subjected to
a process consisting of two steps of enzymatic digestion with (1) collagenase
IV/hyaluronidase, and (2) DNase I followed by (3) trypsin/EDTA. Each enzymatic
step was performed for 20 min at 37ºC, followed by 10 min wash at 4ºC in a
solution of PBS supplemented with 10% fetal bovine serum (FBS) (Gibco,
Mississauga, ON, CAN). Cells released during digestion were passed through a
tissue mesh (45 μm) to obtain a single cell suspension. Next, cells were
separated on a Percoll (Sigma) discontinuous gradient according to a modified
protocol by Worton et al. for hematopoietic stem cell isolation (40) and then
seeded in DMEM/F12 media (Gibco, Mississauga, ON, CAN) supplemented with
10% FBS and antibiotic-antimycotic solution. After 4 days, media was changed
and non-adherent cells were washed with media to leave behind adherent
PMSCs able to form colonies.
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4.2.2. Cell Culture and Incubation in Low Oxygen Tension
For each experiment, two preterm PMSC cell populations were used in triplicate.
Cells were cultured and maintained using DMEM/F12 media supplemented with
10% ES-FBS and FGF-2 (100 ng/mL) (Gibco, Mississauga, ON, CAN). Before
treatments, cells were cultured in DMEM/F12 supplemented 10% FBS only.
Upon treatment, PMSCs were switched to fresh media containing IGF-I or IGF-II
(0 – 300 ng/mL). For IGF-IR neutralizing, cells were grown in serum-free media
for 24-hrs and then switched for 2-hrs in serum-free media with 1.33x final
concentration of 1H7 Ab (in 75% final volume). Secondly, Serum-free media
containing 4x final concentration of IGF-I or -II (in 25% final volume) was added
and incubated for the rest of 24-hrs. Cell cultures were then placed in either a 5%
CO2 incubator or a hypoxia chamber, which was filled with a mix of (1% O 2, 5%
CO2, Balanced N2) (BOC Canada Ltd, Toronto, ON, CAN) for 15 min to ensure
saturation using a Hudson 5590 Oxygen Monitor (Hudson, Ventronics Division,
Temecula, CA, USA). Thereafter, the chamber was placed in a tissue-culture
incubator at 37o C.

4.2.3. Osteogenic Differentiation
PMSCs were plated at 70% confluency in non-differentiation conditions (15%
FBS/DMEMF12) or in presence of osteogenic stimulatory conditions (15%
osteogenic differentiation FBS, 10-8 M Dexamethasone, 50µg/mL Ascorbic acid,
and 3.5 mM β-Glycerophosphate) (Stem Cell Technologies, Vancouver, BC,
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CAN). With IGF-I or -II treatments, 100 ng/mL of either IGF was added
continuously to a reduced FBS level of 2% instead of 15% in either media.
Relative effect of different IGF and oxygen tension treatments on calcium
deposits was compared using alizarin red and alkaline phosphatase staining. The
signaling of MEK/ERK pathway or the PI3K/AKT pathways was inhibited by the
continuous presence of U0126 (5 µM) or LY294002 (10 µM), respectively. To
assess these morphological changes of differentiated vs. non-differentiated, cells
were cultured for 14-days and then fixed with 4% formaldehyde for 30 min at RT.
Then cells were either stained with 1% Alizarin Red solution for 10 min at RT, or
with NBT/BCIP reagents as per manufacturer’s protocol. Both staining were then
solubilized with 10% cetylpyridinium chloride in 10mM sodium phosphate buffer
pH 7.0 as previously described (35). The absorbance of 200 µL solubilized
staining was read at λ=570nm using a plate reader. The absorbance was then
normalized to total protein content per well in micro-grams.

4.2.4. Immunoblotting
Cell lysates were prepared using 1x cell lysis buffer for phospho-proteins
according to manufacturer protocol (#9803, Cell Signaling Technologies,
Burlington, ON, CAN). Protein samples (10-20 μg) from each cell lysate were
resolved by 10% SDS-PAGE, and then transferred onto PVDF membranes
(Millipore, Bedford, MA). The membranes were blocked with 5% bovine-serumalbumin or in 5% non-fat-dry milk in 1x TBS (Tris-buffered saline) for 1 hr at room
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temperature. Blots were then washed in 1x TBS 0.1% Tween 20 (TBS-T) (3x for
5 min) followed by incubation at 4oC overnight with primary antibodies as per
manufacturer’s protocols. Blots then were washed using TBS-T (3x for 10 min)
and were incubated with the corresponding secondary HRP-labelled antibody for
1 hr at RT. Immunocomplexes were detected by ECL and documented using
VersaDOCTM Imaging System (Bio-Rad).

4.2.5. Antibodies
To investigate the IGF-I activated signaling molecules in placental MSCs, we
used the following antibodies: phospho-p44/42 MAPK (#4377), p44/42 MAPK
(#9102) phospho-AKT (Ser473, #4051), AKT (#9272) from (Cell Signaling
Technologies, Burlington, ON, CAN) and IGF-IRα (N-20, sc-712) and IR- α (N20, sc-710) (Santa Cruz Biotech., Santa Cruz, CA, USA). For multipotency
markers, we used OCT3/4 antibody (N-19, sc-8628) (Santa Cruz Biotech., Santa
Cruz, CA, USA) and SOX-2 (2683-1) (Epitomics, Burlington, ON, CAN). For the
osteogenic differentiation markers we used RUNX2 (#8486) from (Cell Signaling
Technologies, Burlington, ON, CAN) and OPN (K-20, sc-1059) from (Santa Cruz
Biotech., Santa Cruz, CA, USA). For loading control, we used pan-Actin Ab-5
(#MS-1295) (Thermo Fisher Scientific, Fremont, CA). The secondary antibodies
used for immunoblotting were goat anti-rabbit (#170-6515), anti-mouse (#1706516) HRP conjugated antibodies (BioRad laboratories, Hercules, CA) or donkey
anti-goat antibody (sc-2020) Santa Cruz Biotech., Santa Cruz, CA, USA).
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4.2.6. Statistical Analysis
All experiments were run in triplicates from three independent experiments each;
whenever possible three or more PMSC primary lines were used from preterm
placentae. All graphs and analyses were generated using GraphPad Prism
Software 5.0 (GraphPad Software, San Diego, CA). A Two-way ANOVA with
Bonferroni post hoc test was used for the PMSC WST1 proliferation assay and
densitometry quantifications. Data are expressed as mean ± standard error of the
mean (SEM); values were considered significant when p<0.05.

4.3.

RESULTS

4.3.1. Effect of low oxygen tension on PMSC osteogenic differentiation
We selected to use preterm PMSCs (11 – 13 wks gestation) to be studied for
differentiation into osteogenic lineage. The progressive morphological changes
over 14 days were greater in room air when maintained in osteogenic
differentiation conditions. Low oxygen tension inhibited osteogenic differentiation
over the same time period (Fig. 4.1A), and enhanced cell proliferation compared
with room air (Fig. S4.1). Alizarin red staining showed that PMSCs could
spontaneously differentiate into an osteogenic-like cells in room air beginning at
day 3, and was limited by low oxygen tension (Fig. 4.1B). Therefore, low oxygen
tension oxygen tension (Fig. 4.1B).
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FIGURE 4.1. PMSC differentiation under low oxygen tension. PMSCs were
cultured for 14-days in non-differentiation or osteogenic differentiation conditions
containing 15% FBS in room air (20% O2) or low oxygen levels (1% O2).
Treatments were stopped after (1, 3, 7, 10, 14 days) for alizarin red staining to
confirm (A) PMSC differentiation morphology and quantified in (B). (Two-Way
ANOVA, P<0.05, n=4, * = significant difference between room air and low oxygen
tension; a= significant difference of differentiation condition in room air, A=
significant difference of differentiation condition in low oxygen tension).
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Therefore, low oxygen tension inhibited differ PMSC spontaneous differentiation
in growth conditions and osteogenic differentiation under differentiation
conditions.

To monitor PMSC stemness during differentiation, stem cell markers OCT4 and
SOX2 were determined, in addition to the osteogenic differentiation and
commitment transcription factor RUNX2. During osteogenic differentiation, OCT4
and SOX2 levels were consistently higher in low oxygen tension compared to
room air (Fig. 4.2A and B). OCT4 levels were unchanged upon differentiation in
either oxygen tension, whereas, SOX2 levels were moderately decreased. At 14
days, RUNX2 levels were increased upon differentiation in room air but were
lower when maintained in low oxygen tension (Fig. 4.2C). Therefore, low oxygen
tension reduced PMSC differentiation by maintaining higher level of pluripotency
genes (higher OCT4 and SOX2), and reducing differentiation commitment
towards the osteogenic lineage (lower RUNX2).

4.3.2. Low oxygen tension preconditioning enhances PMSC osteogenic
differentiation
We evaluated whether preconditioning PMSCs in low oxygen tension, which
maintain multipotency, can enhance differentiation when exposed to
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FIGURE 4.2. Effect of low oxygen on PMSC osteogenic differentiation and
stemness. PMSCs were cultured for 14-days in non-differentiation or osteogenic
differentiation conditions containing 15% FBS in room air or low oxygen levels.
Treatments were stopped after 14 days. Protein levels for A) OCT4, B) SOX2,
and C) RUNX2 were quantified from Immunoblots. Quantification levels shown
were normalized to β-Actin, a protein loading control. (Two-Way ANOVA,
P<0.05, n=3, * = significant difference between room air and low oxygen tension,
# = significant effect by differentiation condition).
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osteogenic differentiation. PMSCs were cultured in non-differentiation or
osteogenic differentiation conditions containing 15% FBS in room air or low
oxygen levels for 14-days as in Fig. 4.1. For preconditioning, PMSCs were
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FIGURE 4.4. Effect of low oxygen tension preconditioning on PMSC
stemness and osteogenic differentiation. Similarly as in Fig. 4.3, PMSCs were
cultured for 14-days in non-differentiation or osteogenic differentiation conditions
containing 15% FBS in room air or low oxygen levels. For preconditioning,
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protein loading control. (Two-Way ANOVA, P<0.05, n=3, * = significant difference
between differentiation and non-differentiation conditions, a = significant
difference by oxygen tension in non-differentiation conditions, A = significant
difference by oxygen tension in differentiation conditions).
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room air. This scenario mimics the in vivo differentiation condition. Alizarin red
staining was returned to same levels as room air by exposure to room air for the
final 7 days of the differentiation course (Fig. 4.3A and 4.3B-left). This was also
confirmed by alkaline phosphatase staining (Fig. 4.3B-right). At the molecular
level, preconditioning in low oxygen tension maintained higher levels of OCT4
and SOX2 which were reduced upon differentiation in room air (Fig. 4.4A and B).
RUNX2 levels were also increased to room air levels upon re-exposure to room
air (Fig. 4.4C). This shows that low oxygen tension programs PMSCs and
enhance/potentiate osteogenic differentiation when exposed to higher oxygen
tension in room air, which is required for completing osteogenic differentiation.

4.3.3. Effect of insulin-like growth factors on PMSC osteogenic
differentiation in low oxygen tension
The additional role of IGFs in mediating the differentiation process in low oxygen
tension was investigated by adding IGF-I or -II for 14 days under continuous
room air or low oxygen tension conditions (Fig. 4.5). There was no increase in
alizarin red staining or increase in spontaneous differentiation in either room air
or low oxygen tension in absence of IGFs (Fig. 4.5A). However, IGF-I was able to
increase earlier spontaneous differentiation in room air. In differentiation
conditions, both IGF-I and IGF-II enhanced osteogenic differentiation in room air
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FIGURE 4.5. PMSC Differentiation is regulated by IGFs. PMSCs were
cultured in non-differentiation or osteogenic differentiation conditions containing
2% FBS and either 100 ng/mL of IGF-I or IGF-II, in room air or low oxygen levels.
Treatments were stopped after 3, 7, and 14 days for (A-B) alizarin red staining to
confirm PMSC differentiation morphology changes into osteogenic lineage and
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between different days of the same IGF condition, # = significant difference by
IGF at the same day compared with 0 ng/mL IGF).
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as confirmed by the increase in alizarin red staining (Fig. 4.5D). In low oxygen
tension, IGF-I and IGF-II enhanced cell condensation (Fig. 4.5B), but did not
increase alizarin red staining (Fig. 4.5F). Interestingly, IGF-I or IGF-II in room air
enhanced alizarin red staining intensity starting at day 3 and reached maximum
by day 7, whereas control (IGF free conditions) required 14 days to reach the
same level (Fig. 4.5D). Therefore, IGF-I and -II enhance differentiation at an
earlier time point in room air.

At the molecular level, low oxygen tension inhibited differentiation as shown by
OCT4 and SOX2 levels (Fig. 4.6A and B). SOX2 was reduced upon
differentiation in room air only (Fig. 4.6A and B). The osteogenic initiation
transcription factor RUNX2 was increased in differentiation in room air but not in
low oxygen tension (Fig. 4.6A and B). OPN, used as a later marker of
differentiation for matrix deposition, increased by day 14 only in room air in
differentiation conditions (Fig. 4.6A and B). Therefore, differentiation in room air
is required to reduce SOX2, and increase RUNX2 and OPN upon PMSC
differentiation.

In osteogenic differentiation, IGFs increased OCT4 levels at day 3 and day 7 in
room air with no effect was observed at day 14. When differentiation occurred in
low oxygen tension, IGFs induced higher levels of OCT4 at all time points (Fig.
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4.7A). Under room air, SOX2 was increased by IGF-I treatment at day 3 but
showed no significant changes following IGF treatment at day 7 or day 14. Under
low oxygen tension, SOX2 was reduced by IGF-I at day 3 and by IGF-II at day 3
and 7 but with no effect at day 14 (Fig. 4.7B). RUNX2 was increased by IGF-I
and IGF-II at the initial stages of differentiation (day 3), and maintained at day 14
(Fig. 4.7C), and low oxygen tension negated this effect. Changes in OPN were
similar to RUNX2 (Fig. 4.7D). Therefore, IGF-I can enhance the PMSC
differentiation towards the osteogenic lineage, more than IGF-II. This
differentiation effect was accelerated by inducing an earlier increase in
osteogenic differentiation markers (RUNX2 and OPN) with a reduction in
pluripotency markers (SOX2).

4.3.4. Effect of insulin-like growth factors on the role of IGF-IR and IR on
PMSC osteogenic differentiation in low oxygen tension
IGF-I and IGF-II signaling is mediated via the interaction with the IGF-IR or the IR
to promote proliferation and differentiation. In room air, IR is increased in
differentiating PMSCs and upregulated by IGF-I; IGF-IR was not affected by IGFs
(Fig. 4.8A and C). In low oxygen tension, the IGF-IR was increased by
differentiation conditions and reduced by IGFs. No change of the IR was
observed in presence of IGFs in low oxygen tension (Fig. 4.8A and B).
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FIGURE 4.7. PMSC multipotency and differentiation is regulated under low
oxygen tension by IGFs. Similarly to Fig. 4.6, PMSCs were cultured for 14-days
in non-differentiation or osteogenic differentiation conditions containing 2% FBS
containing 100 ng/mL of IGF-I or IGF-II in room air or low oxygen levels.
Treatments were stopped after 3, 7, and 14 days. Immunoblotting was used to
detect levels of (A) OCT4, (B) SOX2, (C) RUNX2, and (D) OPN changes induced
by IGFs over the three stop days. Quantification levels were normalized to βACTIN, a protein loading control. (Two-Way ANOVA, P<0.05, n=3, * = significant
difference by time in no IGF conditions, X = significant difference by IGF-I or IGFII in differentiation conditions).
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To specify the role of downstream signaling of ERK1/2 and AKT in mediating
PMSC differentiation, U0126 and LY294002 were used to inhibit the signaling via
the MEK1/2 and PI3K, respectively. In non-differentiation conditions, the addition
of U0126 and LY294002 every 48 hours reduced phosphorylation of ERK1/2
(Fig. S4.2A) and AKT (Fig. S4.2B), respectively. After 14 days, the alizarin red
staining was reduced by LY294002 more than with U0126 (Fig. 4.9A and B).
Also, after 14 days of differentiation, LY294002 increased p-ERK1/2 levels in low
oxygen tension (Fig. S4.3A). AKT phosphorylation was inhibited by LY294002,
and even more in differentiation condition in low oxygen tension conditions (Fig.
S4.3B). Incubation with LY294002 or U0126 for 14 days did not change PMSC
viability (Fig. S4.4); however, differentiation was inhibited (Fig. 10). U0126
increased RUNX2 under differentiation conditions in low oxygen tension, while
OPN was decreased in room air (Fig. 10C and D). LY294002 reduced OCT4,
SOX2, RUNX2 and OPN in differentiation conditions but more in low oxygen
tension (Fig. 10A - D). Therefore, PI3K signaling is required for PMSCs to
maintain

multipotency

in

non-differentiation

condition

and

to

mediate

differentiation in osteogenic differentiation conditions. MEK1/2 inhibited RUNX2
levels in low oxygen tension. Therefore, both signaling pathways are important
for PMSC differentiation depending on oxygen tension, with PI3K signaling being
of greater importance to mediate PMSC differentiation towards the osteogenic
lineage.
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signaling under low oxygen tension. PMSCs were cultured for 14-days in nondifferentiation or osteogenic differentiation conditions containing 2% FBS in room
air or low oxygen levels. During the 14 days, a continuous exposure to (5 μM)
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in (B). (Two-Way ANOVA, P<0.05, n=4, * = significant difference between room
air and low oxygen tension, X = significant difference between differentiation and
non-differentiation conditions, # = significant difference by inhibitor as compared
to DMSO).
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4.4.

DISCUSSION

For the successful use of stem cells for cell based therapies, optimization of stem
cell survival and potency in vitro and preventing cell death in vivo after injection
are major considerations (41). In addition, differentiation towards a progenitor cell
population without residual undifferentiated cells is required (42). In this study,
we

used

low

microenvironment

oxygen
to

tension

understand

and
their

IGFs

to

manipulate

interactions

to

the

PMSC

improve

PMSC

differentiation towards the osteogenic lineage. We found that low oxygen tension
delayed or inhibited PMSC differentiation and reduced the effects of IGF-induced
earlier osteogenic differentiation. In vitro, osteogenic differentiation follows a
three phase process: a differentiation phase (days 0 – 5), a matrix formation
phase (days 5 – 12) and a mineralization phase (days 12 – 19) (27). In this study,
we investigated the role of IGFs in combination of low oxygen tension in the
commitment and matrix formation phases of PMSC differentiation (days 0 – 14).
We demonstrated that RUNX2 is expressed in early differentiation where low
oxygen tension impeded its increased levels. OPN, as a late osteogenic
differentiation marker, was also reduced by low oxygen tension. IGFs enhanced
PMSC differentiation only in room air (a greater effect of IGF-I than IGF-II) where
low oxygen tension abolished this process. Similarly, this has been shown
previously that IGF-I increases the early differentiation marker RUNX2, and the
late markers Type-I collagen and alkaline phosphatase (35).
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significant difference between differentiation and non-differentiation conditions, #
= significant difference by inhibitor as compared to DMSO).
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The role of the transcriptional network of OCT4, SOX2 and NANOG in
maintaining pluripotency and suppressing differentiation was elucidated recently
in mouse and human embryonic stem cells. In mESCs, mesodermal lineage
specification is determined by OCT4 and SOX2 expression levels: a balanced
expression maintains pluripotency, upregulation of OCT4 relative to SOX2
induces mesendodermal lineage specification, and downregulation of OCT4
relative to SOX2 induces neural ectodermal lineage specification (43, 44). In
human ESCs, OCT4 maintains an embryonic stem cells state and represses
extraembryonic differentiation, while SOX2 is required to suppress the
differentiation towards the mesendodermal and NANOG suppresses the
ectodermal linage (45). In PMSCs, osteogenic differentiation increased the levels
of OCT4 and decreased the levels of SOX2, as would be expected in a
mesodermal lineage differentiation. Low oxygen tension increased both OCT4
and SOX2 levels, thereby maintaining a more multipotent state even under
differentiation conditions (46). Recently, OCT4 was shown to be required for in
vivo and in vitro differentiation processes as it participates in the downregulation
of the pluripotency program and that OCT4 deficient cells are unable to
differentiate (47). In this study, we observed that differentiating PMSCs increased
OCT4 levels prior to differentiation.

Oxygen tension is increasingly recognized as an important factor of the stem cell
niche for proliferation, migration, metabolism and differentiation. In bone
fractures, oxygen level can go as low as 0.1% (~0.76 mm Hg) (27, 48). Also,

165
oxygen tension at the fracture site of the femoral head can be as low as 17.319.9 mm Hg, and even lower, at 1 cm away from fracture site (12.5-12.8 mm Hg)
(49). Therefore, preconditioning of PMSCs in low oxygen tension, before
application into bone fracture, can improve survival of PMSCs and therefore
healing of the tissue in the injury site of scarce oxygen tension just as
hypothesized previously (25). This was confirmed as reported previously that low
oxygen tension preconditioning of MSCs enhances successful engraftment to
infarcted myocardium, reduced cell death and increased angiogenesis (50).

The inhibition of differentiation by low oxygen tension could be due to the
metabolic switch requirement for osteogenic differentiation, which relies on the
upregulation of mitochondrial function and aerobic respiration seen in room air
(28). Low oxygen tension can hinder this process by reducing energy production
(ATP) by glycolysis alone, which is not sufficient for the high energy demanding
differentiation processes required for matrix deposition and mineralization. In our
study, we observed that re-exposure of differentiating PMSCs to higher oxygen
tension in room air led to a more robust PMSC differentiation.

The role of the IGF-IR in osteoblast differentiation (36) and in in vivo bone
development (37, 51) is well recognized. However, the role of the insulin receptor
is unknown. The IR has two isoforms IR-A and IR-B and it was demonstrated that
IR-B is abundantly expressed in differentiating MSCs and mature osteoblasts
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than IR-A which was abundantly expressed in proliferating cells (52). In this
study, we showed that the IR might play a role in the differentiation process of
PMSCs opposite to the expression of IGF-IR. This finding suggests that
differentiating osteoblasts expresses higher IR levels to accommodate the higher
energy demand in differentiating condition and utilizing more glucose for
metabolism, especially via IR-B signaling which is enhanced by IGF-I.

It was shown previously that signaling through IGF-IR in MSCs during
differentiation is regulated by PI3K/AKT, and not MAPK, signaling (in a positive
feedback loop) to inhibit apoptosis of osteoblasts (51). In this study, we showed
that the inhibition of PI3K caused a significant reduction in pluripotency markers
(OCT4 and SOX2) and osteogenic markers (RUNX2 and OPN), suggesting that
PI3K is required not only to maintain multipotency but also to regulate PMSC
differentiation. Interestingly, MEK/ERK signaling may also play a role in low
oxygen tension by reducing the levels of RUNX2 and OPN as they were elevated
by inhibiting MEK1/2, suggesting a possible role for MEK1/2 to suppress
osteogenic differentiation.

In conclusion, PMSCs successfully differentiate towards the osteogenic lineage,
as an alternative source for MSC other than the more popular bone marrow MSC
for tissue regeneration therapy. PMSC preconditioning in low oxygen tension and
the use of IGFs (mainly IGF-I) to stimulate PMSCs is promising strategy to
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generate osteogenic progenitor cells for tissue regeneration therapy for bone
deficiencies. However, whether this strategy will enhance successful engraftment
for the regenerative therapy in OI or bone fractures will require studying in animal
models.

4.5.
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FIGURE S4.1. PMSC proliferation is more active in low oxygen tension
regardless of the differentiation conditions. PMSCs were cultured for in nondifferentiation or osteogenic differentiation conditions containing 2% FBS in room
air or low oxygen levels. Treatments were stopped after 3, 7, and 14 days for cell
counting using a hemocytometer. (Two-Way ANOVA, P<0.05, n=6, * = significant
difference between room air and low oxygen tension, # = significant difference
between day 3 and day 7 and 14).
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FIGURE S4.2. Inhibition of MEK1/2 and PI3K inhibits the phosphorylation of
ERK1/2 and AKT. PMSCs were treated over 48-hrs period the time between
media changes during a regular PMSC differentiation course. Treatment was
stopped after 3, 6, 12, 24, and 48 hrs after inhibition by adding (5 μM) U0126 or
(10 μM) LY294002 in presence of 2% FBS. Levels of p-ERK and p-AKT as
shown in the immunoblots were normalized to total kinase levels and β-Actin, a
protein loading control. (Two-Way ANOVA, P<0.05, n=4, a = significant
difference by the presence of the inhibitor over time).
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FIGURE S4.3. Inhibition of MEK1/2 and PI3K affects ERK1/2 and AKT
signaling in PMSCs. PMSCs were cultured for 14-days in non-differentiation or
osteogenic differentiation conditions containing 2% FBS in room air or low
oxygen levels. During the 14 days, a continuous exposure to (5 μM) U0126 or
(10 μM) LY294002 containing media was changed every 48-hrs. Treatments
were stopped at 14 days and immunoblots were used to detect levels of ERK1/2
and AKT changes induced by signaling inhibition. Quantification levels were
normalized to total kinase level and β-Actin, a protein loading control. (Two-Way
ANOVA, P<0.05, n=3, * = significant difference between room air and low oxygen
tension, # = significant difference by adding the inhibitor, X = significant
difference between differentiation and non-differentiation conditions).
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FIGURE S4.4. Effect of MEK1/2 and PI3K inhibitors on PMSC viability
during differentiation. PMSCs were cultured for 14-days in non-differentiation
or osteogenic differentiation conditions containing 2% FBS in room air or low
oxygen levels. During the 14 days, a continuous exposure to (5 μM) U0126 or
(10 μM) LY294002 containing media was changed every 48-hrs. Treatments
were stopped at 14 days and cell viability was measured by WST1 reagent
assay. (Two-Way ANOVA, P<0.05, n=4, * = significant difference between room
air and low oxygen tension).
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5.1. Summary and Perspectives
This study provides an insight into the understanding PMSC fate determination
by IGFs and low oxygen tension. We found that low oxygen tension, a
physiologic oxygen tension in stem cell niches in vivo, can regulate PMSC fate
(multipotency or differentiation) in the presence of IGFs. First, low oxygen tension
was found to enhance the IGF-I facilitated proliferation and multipotency
response depending on PMSC gestational age (Chapter One). Second, low
oxygen tension was found to enhance IGF-II expression and maintain PMSC
multipotency by signaling via both the IGF-IR and the IR (Chapter Two). Lastly,
low oxygen tension was found to inhibit the IGF-I stimulated osteogenic
differentiation and maintain PMSC in a higher stemness state (Chapter Three).

In this study, maintaining stem cells in low oxygen tension and improved the
stemness possibly by mimicking the in vivo conditions. The manipulation of the
IGF receptors (IGF-IR, IR and HR) signaling by IGFs in a concentration and timedependent manner was important to understand the stem cell behaviour. IGF-II,
more than IGF-I, maintained a higher multipotency state in low oxygen tension,
whereas IGF-I, more than IGF-II, improved the differentiated state of PMSCs in
higher oxygen tension (room air). Also, low oxygen tension maintained a higher
multipotent state even in differentiation-promoting culture conditions. Therefore,
these results have implications for (1) defining the placental microenvironment
during development that maintains PMSCs in vivo in a multipotent state; and (2)
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identifying the molecular mechanisms underlying these microenvironmental
changes in vitro in PMSCs to maintain multipotency or differentiation. We
demonstrated in this study that during placental development, low oxygen
tension, gestational age and IGF-axis signaling, can define the in vivo conditions
that determine stem cell fate (multipotency or differentiation).

5.1.1. The microenvironment is a major determinant of stem cell fate
changes in vivo and in vitro
5.1.1.1. Gestational Age
Placental mesenchymal stem cells (PMSCs) used in this study were isolated
from chorionic villi of preterm (11–13 wks) and late third trimester (37–39 wks)
human placentae. In vivo, during chorionic villi formation, fetal mesenchyme
migrates into primary villi at early gestation between 5th and 7th weeks, until the
12th week of gestation when terminal villi are formed, and become the majority of
villous type at term gestation (1, 2). Chorionic villi have the highest abundance of
mesenchymal cells (undifferentiated and differentiated) that decreases with
gestation; they are still found in term placentae but only 1% of total tissue by
volume (3). This was described as a thinning that occurs to the stromal layer,
hence a decreased number of mesenchymal tissue cell populations per section
of chorionic villi (4). Placental gestational age can therefore be a determining
factor in the abundance of PMSC isolated and colony formation capacity as they
originate from the mesenchymal stromal layer of the chorionic villi. As
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demonstrated by increased expression of stem cell markers, the higher
proliferation capacity and earlier osteogenic differentiation changes, preterm
PMSCs may have different characteristics and a more primitive state than term
PMSCs. Although, both populations of PMSCs can proliferate in response to
IGF-I and low oxygen tension and can differentiate into all lineages obtained by
PMSCs.

This

can

be

naturally

occurring

in

vivo

by

the

changing

microenvironment (gradual increase in oxygen tension and growth factor levels)
of the chorionic villi with gestation to program stem cells; therefore PMSCs show
distinct response to the same stimulation condition of IGFs and low oxygen
tension in vitro. Thus, advancing in gestation can lead to some of the differences
in the PMSC multipotency state and differentiation potential that should be
considered when isolating PMSCs from the placenta.

Low oxygen tension was shown to narrow the differences between the two types
of PMSCs that were seen in room air of which term PMSCs could regain higher
stemness and an increased proliferation level comparable to preterm PMSC.
Hence, maintaining PMSCs in low oxygen tension in self-renewal supportive
conditions is permissive to maintain stem cell markers, regardless of
developmental stage of PMSCs. Also, preterm PMSCs were more responsive to
IGF-I and IGF-II stimulation than term PMSCs. However, as shown previously,
first trimester placenta provides a valuable source of MSCs which have greater
expansion potential than adult bone marrow MSCs and are an excellent source
for therapeutic application (5). Likewise, term human placenta is an abundant
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source of chorionic villi MSCs and to have a high therapeutic potential as these
cells can differentiate into the three germ layer cells (6). However, this is the first
study to put into perspective the comparison of preterm and term PMSC
multipotency control. Overall, the human placenta at different gestation is an
excellent source of MSCs that may have different capacities due to the different
microenvironment in vivo.

5.1.1.2. Low Oxygen Tension
The changing extracellular microenvironment is a major factor to regulate stem
cell proliferation and differentiation in many developing tissues, including the
placenta. Oxygen tension doubles between the first and second trimesters from
about 18 mm Hg to 40 mm Hg, and then gradually increases to approximately 60
mm Hg and maintained up to the third trimester (7, 8). This oxygen gradient is
created starting at the first trimester of pregnancy (higher at the endometrium
compared with fetal stromal layer) by the undeveloped fetoplacental circulation,
resulting in low oxygen tension conditions, which is necessary for early
development (9). In fact, blood flow from the spiral arteries into the intervillous
space is prevented by the endovascular trophoblasts until the 12 th week of
gestation, to protect the early embryo from the excessively high oxygen levels
(10). Therefore, preterm PMSCs naturally reside in low oxygen tension
conditions compared to the later gestation PMSCs, and hence may adapt better
to low oxygen tension conditions in vitro than term PMSCs.
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The hypoxia inducible factor (HIF) system is activated more in early pregnancy. It
is an upstream activator of VEGF, which is highly expressed in early gestation
and decreased by third trimester, a stage when the placenta is well vascularized
and less hypoxic (9). HIF-1α and HIF-2α expression are increased during the first
trimester, peaking between 7-10 wks of gestation and declining thereafter with
development having the lowest levels at term gestation (11). This HIF signaling
initiates the development of the fetoplacental circulation by increasing
proliferation of trophoblast cells and stromal mesenchymal cells and forming new
capillaries, in the oxygen deprived stromal layer. This is triggered by growth
factors, such as b-FGF, VEGF and PlGF (12). In this microenvironment, IGF-II
and not IGF-I, is a major signaling factor targeted directly by HIF-1 regulation to
induce an increased transcription (13, 14), leading to increased IGF-II levels in
early gestation. In turn, IGF-I and IGF-II stimulation can stabilize HIF-1α and HIF2α (11). Therefore, low oxygen tension and IGFs may have a crosstalk with a
positive feedback mechanism. In our PMSCs, low oxygen tension upregulated
IGF-II expression at the mRNA level even in presence of IGF-I or IGF-II,
mirroring the in vivo microenvironment of the placenta.

5.1.1.3. Insulin-like Growth Factor System
The PMSCs we studied are derived from chorionic villi and they reside in the
perivascular region of the fetal compartment where the exchange of nutrients,
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oxygen and waste between the mother and the fetus. Therefore, they are in
contact with factors from both the fetal and maternal circulations, and hormones
and factors synthesized by the syncytiotrophoblasts, cytotrophoblasts and the
chorionic mesoderm. IGF-I and IGF-II are synthesized in the placenta by the
chorionic mesoderm (where PMSCs reside), where IGF levels do not relatively
change during gestation across the three trimesters (15). In the fetus, IGFs are
one of the most abundant growth factors in the circulation that are just
downstream signaling of the GH axis at the level of organs, tissues and cells
(16). In the placenta, a pituitary GH variant, the placental lactogen/chorionic
somatomammotropin, functions in a paracrine fashion to upregulate IGF
expression and sustain an increased growth in the placenta (17). In the fetus, the
liver is the major source of circulating IGFs, whereas in the placenta, as in many
extra-hepatic tissues, IGFs are expressed in a paracrine/autocrine fashion
regulated in part by placental GH (16, 18). It has been shown that IGF-I and IGFII paracrine/autocrine signaling were required for first trimester placental primary
fibroblast increased survival, proliferation, and migration and decreased
apoptosis (19). Our PMSCs express their own IGFs, both IGF-I and IGF-II, which
promoted localized paracrine/autocrine cellular growth as was shown in serum
free growth conditions.
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The ability of IGF-I and IGF-II to maintain PMSC multipotency or
differentiation
The importance of IGF function in the human placenta stems from their role in
mediating increased growth, reduced apoptosis, and induced differentiation of
the different cells of the chorionic villi (20, 21). Placental development is
dependent on IGF and IGF receptor expression, however, the relative role of
IGF-I and IGF-II can vary depending on spatial and temporal expression during
pregnancy (22). The cord blood IGF-I concentration, and not IGF-II, is correlated
with birth weight fetal growth restriction in humans, whereas the placenta is more
correlated with IGF-II (23). This is similar to the mouse in which Igf2 knockout
severely reduced placental growth (24). In the human placenta, IGF-II mRNA is
expressed in the villous mesenchymal core, where PMSCs reside, at all three
trimesters (22). IGF-II plays a role in migration, proliferation, and decrease
apoptosis of extravillous- and cyto-trophoblasts in the placenta (11), whereas
IGF-I is implicated in later gestation, and is involved in cytotrophoblast
differentiation. In PMSCs, we showed that both IGF-I and IGF-II induced a
concentration and a time response increased proliferation in low oxygen tension
and that IGF-I enhanced spontaneous and osteogenic directed differentiation.

IGF Receptor Expression
In the placenta, both IGF-IR and the IR are expressed mainly in the microvillous
membrane of the proliferating cytotrophoblasts in the first trimester, with a switch
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to an expression in the basal membrane facing fetal circulation at term gestation
(15). However, there is no information on the localization of the IGF-IR or IR in
PMSCs in the placenta during different gestational ages. In PMSCs, IGF-IR and
IR are highly expressed in preterm PMSCs that decline with gestational age. This
higher expression level of both receptors correlates with the higher IGF-II levels
expressed at the low oxygen tension conditions at early gestation. The role of the
IR in placental growth was suggested by the dual knockout mouse for Igf2 and
Igf1r that was more severely growth restricted than Igf1r knockout alone,
indicating that IGF-II can signal through another receptor to mediate placental
growth (24); this can also be the case in human placenta. IR signaling (via IR-A)
was confirmed to mediate placental growth via IGF-II signaling in early gestation
(25); the IGF-IR is expressed abundantly by the middle of the first trimester—
becoming of higher affinity to IGFs with advanced gestation (26). This
consequently spares the most abundant IGF-II signaling for the IR-A rather than
IGF-IR during early gestation. We have observed the dual expression of IGF-IR
and IR in PMSCs, which can favour the formation of hybrid receptors IGF-IR/IR
that preferentially binds to IGFs rather than insulin. In the human placenta, 55%
of the IGF-IR is assembled in the hybrid form to specifically bind IGF-I than
insulin (27). IR-A and IGF-IR/IR-A (HR-A) are upregulated in various cancers
(breast, thyroid, myosarcoma, osteosarcoma, cervical and prostate) to mediate
more aggressive malignant cancer forms (28). Therefore, HR-A can be involved
to maintain a more naïve state of cancer stem cell development. A similar
biological function may be present in PMSCs in vivo.
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PMSC fate is likely determined by the differential signaling due to receptor
affinity, choice of receptor (IGR-IR, IR, hybrid IGF-IR/IR) and the combination of
downstream receptor signaling cascades. At the receptor level, low oxygen
tension increased IR-A as well as IGF-IR expression even in presence of high
levels of IGFs. IGF-I and IGF-II may utilize different signaling molecules as IGFIR has greater affinity to IGF-I than IGF-II, and IR-A has greater affinity to IGF-II
than IGF-I (29). Therefore, the increased expression of pluripotency triad
transcription factors by IGF-II maybe transduced via IR-A. Also, in PMSCs, IR
has played a role in increasing proliferation in low oxygen tension in addition to
IGF-IR. This could be because IR-A, which unlike IR-B, can induce a mitogenic
signal similar to IGF-IR suggesting that the increased abundance of IR or HR-A
in low oxygen tension can induce proliferation. Therefore, PMSCs cultured in low
oxygen tension can utilize different signaling cascades to enhance PMSC
proliferation and multipotency.

IR was also increased in differentiating PMSCs towards the osteogenic lineage in
room air but not in low oxygen tension. A recent report showed that IR increases
with a higher ratio of IR-B to IR-A in differentiating osteoblasts (30). Unlike IR-A,
which mediates mitogenic actions involved in increased cell proliferation,
atherosclerosis and cancer, IR-B is responsible for metabolic action to facilitate
metabolism, cell differentiation and increased longevity (28). Hence, IR-A is
required for stem cell self-renewal while IR-B is required following differentiation.
In osteogenesis, a metabolic switch is required for a complete osteogenic
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differentiation to upregulate mitochondrial count and cellular aerobic respiration,
which is obscured by low oxygen tension (31). Therefore, an upregulation of IR-B
may increase insulin signaling for glucose uptake which is required as an energy
source in aerobic respiration for increased ATP production.

Kinase Signaling
We demonstrated that ERK1/2 and AKT are important downstream mediators of
IGF signaling in stimulating proliferation and multipotency of PMSCs in vitro that
may be applicable in vivo. ERK1/2 is important in mediating cell proliferation and
growth, whereas AKT is important in cell survival and metabolism. These two
signaling cascades are important for regulating PMSC proliferation and
maintaining multipotency. How these two signaling cascades interact in
regulating stem cell multipotency at the molecular level has not been delineated.
A recent identification of 14 phosphorylation sites on OCT4, away from the DNA
binding site, revealed three putative phosphorylation sites for ERK2 at S111,
T118, and S355 (32) which may provide a direct link to IGF signaling in stem
cells; however, the role of OCT4 phosphorylation is not yet clear. Also, ERK2 has
been shown to interact directly with chromatin at the SOX2 promoter regions to
maintain its transcription (33); in addition, ELK1 (ERK2 downstream substrate)
can interact with the repressive complex polycomb group protein complex 2
(PRC2) to repress differentiation genes and therefore can maintain ESC
pluripotency (33). On the other hand, AKT has been shown to interact directly
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with EZH2, a component of PRC2, to phosphorylate it on Ser-21 (34). Thus, IGFs
can stimulate phosphorylation of EZH2 via AKT pathway and reduce the capacity
of PRC2 to trimethylate histone H3K27 in promoter regions of OCT4 and
promote the de-repression of the OCT4 promoter transcription and maintain
multipotency (unpublished data).

During differentiation, MEK1/2 is important for osteoblast differentiation and
skeletal development, as it is required for RUNX2 phosphorylation and
transcriptional activity (35, 36). Also, the PI3K plays an important role in
osteogenic differentiation (37). However, the role of PI3K and MEK in facilitating
and inhibiting MSC differentiation is still controversial (37). In a previous study,
PI3K was shown to be essential in mediating osteoblast differentiation of MSCs,
while MEK repressed MSC differentiation towards the osteogenic lineage (38). In
addition, IGF-I expression in MSCs increased osteogenic differentiation for bone
repair, which was mediated via IRS1-PI3K (39). In our PMSCs, both PI3K and
MEK were required for osteogenic differentiation in room air, and their inhibition
repressed complete differentiation. The role of PI3K was greater than MEK in
mediating differentiation in both low oxygen tensions and room air, while in low
oxygen tension MEK showed a role in repressing differentiation. Therefore, low
oxygen tension can change the role of signaling kinases in mediating PMSC
differentiation. However, these signaling differences still need investigation to
determine the mechanisms of how PI3K and MEK can mediate the differentiation
process of PMSCs in low oxygen tension.
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5.1.1.4. PMSC Fate Changes
Low oxygen tension improved the stemness level of PMSCs (increased OCT4,
SOX2 and NANOG expression) and increased proliferation. The enhanced stem
cell gene expression can be mediated via HIF-2 direct interaction with all three
pluripotency genes to increase transcription (40, 41). OCT4, SOX2 and NANOG
gene expression was upregulated by longer stimulation time by IGFs but
decreased by increased IGF concentration. In our study, we mainly focused on
OCT4, the master regulator of pluripotency. OCT4 mutation/loss is embryonic
lethal (42), whereas ectopic overexpression causes dedifferentiation in somatic
cells (43). In MSCs, ectopic expression of OCT4 increased proliferation and
maintained

cell

morphology

during

prolonged

passaging

and

inhibited

spontaneous differentiation (44). In PMSCs, IGF-I and IGF-II increased OCT4
expression (more with IGF-II), confirming that IGFs can enhance stemness in
combination with low oxygen tension.

MSCs differentiate into the mesodermal lineage and also can differentiate
towards endodermal and ectodermal lineages; however, this phenomenon of
transdifferentiation is still controversial in vivo (45). We have found that PMSCs
can differentiate towards the mesodermal lineage (adipose, osteogenic,
endothelial, myogenic), and ectodermal cells (neuron-like cells expressing
Nestin). MSCs transdifferentiation occurs due to MSC heterogeneity, which is
referred to a mixture of progenitor cells at different stages of commitment to
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multiple lineages (45). In vivo, MSC plasticity is needed to adapt to varying
stressors and microenvironmental demands to repair tissue damage (46).
Therefore, MSCs express genes from at least two germ layers and pluripotency
triad genes demonstrating a “multi-differentiation” potential awaiting the fate
restriction signal (47). Therefore, differentiation of MSCs is not a simple on/off
switch but is regulated through transcription of specific genes depending on the
microenvironment. Osteogenic differentiation is a classical mesodermal lineage
originated from the MSC in the bone marrow. Therefore, osteogenic
differentiation of PMSCs, which does not normally occurs in vivo, demonstrates
PMSC plasticity.

In the placenta, PMSCs can differentiate into four mesodermal lineage cells:
macrophage-like mesenchymal cells, haemangioblastic cords, pericytes and
stromal fibroblasts (48), where IGFs and low oxygen tension can play an
important role (49, 50). In this study, we show that PMSCs can differentiate into
mesodermal

osteoblasts

expressing

RUNX2,

osteopontin,

and

alkaline

phosphatase. Moreover, differentiated osteoblasts deposit bone matrix and stain
positive for calcium deposition. During this process, room air was a major
facilitator of differentiation, while low oxygen tension repressed this effect. Low
oxygen tension increased OCT4 and SOX2 and lowered RUNX2 and
osteopontin. IGFs facilitated an earlier commitment towards osteogenic
differentiation with higher levels of OCT4 and SOX2. However, IGF-I was more
potent than IGF-II to enhance osteogenic differentiation.
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The ratio between OCT4 and SOX2 is important for mesodermal differentiation
with lower SOX2 (51) and higher OCT4 (52, 53). In PMSCs, OCT4 levels did not
decrease post differentiation and was enhanced by IGFs; however, SOX2 levels
were

decreased

confirming

mesodermal

differentiation.

In

fact,

OCT4

overexpression in MSCs enhanced adipogenic and chondrogenic differentiation
by increasing differentiation markers and promoting the complete differentiation
morphology

(44).

Therefore,

OCT4

might

be

required

for

osteogenic

differentiation. SOX2 overexpression inhibits osteoblast differentiation by
promoting higher proliferation (54). Therefore, the reduction in SOX2 levels in
osteogenic

differentiation

can

also

confirm

PMSC

differentiation.

The

coexpression of RUNX2 and osteopontin is a marker of progenitor osteoblasts
formation (55). We found that an increased RUNX2 expression occurs early in
osteogenic differentiation, while osteopontin levels were increased by the end of
differentiation period confirming osteogenic commitment.

5.2. Overall Conclusions
In this study, we showed that the human placenta is a valuable source of
mesenchymal stem cells that can be expanded and differentiated in vitro by
manipulating the surrounding microenvironment. Low oxygen tension is the major
regulator of stemness by enhancing PMSC proliferation and pluripotency gene
expression. As summarized in Figure 5.1, although PMSCs from different
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gestations respond differently to IGF stimulation, low oxygen tension enhances
PMSC proliferation and pluripotency gene expression levels. Low oxygen tension
activates ERK1/2 signaling, while IGFs activates AKT signaling of which both are
required to maintain PMSC proliferation and multipotency. PMSC fate changes
were differently mediated by IGFs: IGF-I induced differentiation and IGF-II
maintained higher PMSC stemness. Low oxygen tension decreases spontaneous
differentiation and inhibits PMSC osteogenic differentiation but can enhance
differentiation if re-exposed to room air. Therefore, to maintain PMSCs in
multipotent state, PMSCs from different gestations should be cultured under IGFII and low oxygen tension conditions, whereas, to differentiate PMSCs to
progenitor cells, PMSCs should be cultured under IGF-I and room air conditions.

Overall, mimicking the in vivo microenvironment of placental mesenchymal stem
cells can improve the in vitro culture conditions for tissue regeneration therapy.
And also, priming PMSCs by IGFs and preconditioning by low oxygen tension
are important steps to improve PMSC growth, multipotency, and differentiation
that can improve PMSC survival and differentiation potential for tissue
regeneration.
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Figure 5.1. stem cell fate in low oxygen tension and insulin-like growth
factor conditions. PMSCs are isolated from preterm and term gestations. To
maintain PMSCs in a multipotent state, low oxygen tension can activate
endogenously the ERK1/2 pathway while IGFs activate the AKT signaling
pathways. Both signaling pathways are indispensible for PMSC proliferation and
pluripotency gene expression. PMSC spontaneously differentiate towards the
osteogenic lineage if grown in room air conditions, whereas, self-renewal is
maintained if PMSCs are maintained under low oxygen tension conditions. IGF-I
is shown to drive PMSC differentiation, while IGF-II can maintain PMSC
multipotency and higher stemness state. Low oxygen tension inhibits PMSC
osteogenic differentiation by maintaining higher pluripotency gene levels and
lower osteogenic differentiation proteins and transcription factors.
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5.3. Limitations and Future Studies
A comparative study of MSCs from chorionic villi of different gestations and
umbilical cord blood with bone marrow and embryonic stem cells can improve
our understanding of the hierarchy of multipotency of stem cells from different
placental sources. Information about IGF-I or -II concentration in the human
placenta during different gestational ages is lacking; however, we inferred from
the concentration of either ligand in the umbilical cord blood to be 100 ng/mL and
300 ng/mL of IGF-I or -II, respectively. We used 10, 50, up to 100 ng/mL of either
IGF-I or -II; as the highest reached by IGF-I as measured by the umbilical cord
blood to equalize the molecular concentration of both IGFs; however, we may
need to increase IGF-II concentration to 300 ng/mL, mimicking the in vivo
conditions, to see more physiological effect at term gestation placenta
development. Also, the combination of both IGFs in one treatment may delineate
different effects on PMSC multipotency or differentiation as both IGFs coexist in
vivo.

For further experimentation, it is important to synchronize cells by serum
deprivation before the treatment by IGFs. Serum deprivation was not used here
as we judged that in a physiological condition in vivo no withdrawal of all growth
factors and cytokines is possible all at once. Monitoring the cell surface markers
CD73, CD105, CD117 expression during IGF stimulation will give an indication of
how

multipotency

changes

during

stimulation

time

in

proliferation

or
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differentiation conditions. An inhibition by siRNA or an ectopic expression of
OCT4 would delineate the role of OCT4 in response of IGFs in self-renewal and
differentiation conditions. OCT4 localization is important for its function; therefore
nuclear vs. cytoplasmic fractionation and immunocytochemistry experiments
would be essential to show the dynamics of OCT4 during differentiation. This
becomes of importance when the high expression of OCT4 in differentiation
conditions is due localization and not function.

The use of a phospho-kinase array could specify the interacting adaptor and
signaling protein with the IGF-IR upon stimulation by IGFs under the two different
oxygen tensions. Knockdown studies of IGF-IR or IR can improve the
understanding of receptor role in mediating PMSC differentiation and the
prolonged proliferation effect in IGF and oxygen tension changes. Specific
inhibitors for ERK1/2 and/or AKT could specify the role of these two kinases in
IGF mediated proliferation and differentiation effects as MEK1/2 and PI3K have
more targets than just ERK1/2 and AKT. Also, using dominant negative kinases
can help identify the role ERK1/2 and AKT in the differentiation process. As IGFIR and IR-A/-B expression change during differentiation, it is important to use a
real-time PCR to identify the receptor level changes and determine whether
expression changes are mediated by IGFs and low oxygen tension.
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Extending the differentiation protocol to 21 or 28 days can improve and complete
the osteogenic differentiation and perhaps lower the OCT4 expression to minimal
levels. This can confirm full mineralization correlating with higher levels of
osteocalcin and loss of RUNX2 and osteopontin in the mature osteoblast
phenotype. In line with RUNX2 phosphorylation, we need to understand the
phosphorylation changes induced by low oxygen tension and IGFs upon
differentiation stimulation.

Besides osteogenic differentiation, we can study the effect of low oxygen tension
on chondrogenic differentiation, which is known as an avascular tissue and
requires low oxygen tension. Also, as PMSCs naturally develop into endothelial
cells, differentiating PMSCs into endothelial cells will improve our understanding
of the natural development of chorionic villi during gestation.

Changes in PMSC fate triggered by the microenvironmental factors can cause
reprogramming effects that can change the epigenetic profile of initial genes. It is
of interest to understand the epigenetic changes by IGFs and low oxygen tension
to maintain multipotency or mediate differentiation. DNA methylation analysis by
bisulfite sequencing or enrichment of variant histones by ChIP analysis, we can
identify the state of OCT4, SOX2 and NANOG promoter regions and understand
the changes upon differentiation towards the osteogenic lineage at RUNX2
promoter.
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The optimal use of PMSCs is for tissue regeneration therapies. Priming PMSCs
with IGFs and preconditioning with low oxygen tension should be used into
animal models to prove the beneficial effects of these two conditions on PMSC
engraftment and survival. Such models can include pancreatic injury or brain
ischemia. Also, with osteogenic differentiation abilities of PMSCs, we can study
the benefits of either using fully multipotent PMSCs or osteoblast progenitor cell
for engraftment into animal model of osteogenesis imperfecta; and whether low
oxygen tension and IGFs can improve bone gain and total growth.

5.4. Significance
The manipulation of PMSCs by IGFs and low oxygen tension can help
understand stem cell development in vivo and define the in vitro cell culture
conditions for optimal use in tissue regeneration therapies.
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Cancer, the following credit line applies.
Adapted by permission from Macmillan Publishers Ltd on
behalf of Cancer Research UK: [JOURNAL NAME] (reference
citation), copyright (year of publication)
7. Translations of 401 words up to a whole article require NPG
approval. Please
visithttp://www.macmillanmedicalcommunications.com for
more information.Translations of up to a 400 words do not
require NPG approval. The translation should be credited as
follows:
Translated by permission from Macmillan Publishers Ltd:
[JOURNAL NAME] (reference citation), copyright (year of
publication).
Note: For translation from the British Journal of
Cancer, the following credit line applies.
Translated by permission from Macmillan Publishers Ltd on
behalf of Cancer Research UK: [JOURNAL NAME] (reference
citation), copyright (year of publication)
We are certain that all parties will benefit from this agreement and wish you the best in the
use of this material. Thank you.
Special Terms:
v1.1

If you would like to pay for this license now, please remit
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this license along with your payment made payable to
"COPYRIGHT CLEARANCE CENTER" otherwise you will be
invoiced within 48 hours of the license date. Payment should
be in the form of a check or money order referencing your
account number and this invoice number RLNK501167486.
Once you receive your invoice for this order, you may pay
your invoice by credit card. Please follow instructions
provided at that time.
Make Payment To:
Copyright Clearance Center
Dept 001
P.O. Box 843006
Boston, MA 02284-3006
For suggestions or comments regarding this order, contact
RightsLink Customer
Support:customercare@copyright.com or +1-877-622-5543
(toll free in the US) or +1-978-646-2777.
Gratis licenses (referencing $0 in the Total field) are free.
Please retain this printable license for your reference. No
payment is required.
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